

Official Protocol Title:	A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Japanese Adults 65 Years of Age or Older
NCT number:	NCT05633992
Document Date:	29-Aug-2022

Title Page

**THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE
CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP &
DOHME LLC, RAHWAY, NJ, USA (MSD).**

Protocol Title: A Phase 3, Randomized, Double-blind, Active Comparator-controlled
Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in
Pneumococcal Vaccine-naïve Japanese Adults 65 Years of Age or Older

Protocol Number: 009-00

Compound Number: V116

Sponsor Name:

Merck Sharp & Dohme LLC
(hereafter called the Sponsor or MSD)

Legal Registered Address:

126 East Lincoln Avenue

P.O. Box 2000

Rahway, NJ 07065 USA

Regulatory Agency Identifying Number(s):

IND	Not Applicable
-----	----------------

Approval Date: 29 August 2022

Sponsor Signatory

Typed Name:
Title:

Date

Protocol-specific Sponsor contact information can be found in the Investigator Study File Binder (or equivalent).

Investigator Signatory

I agree to conduct this clinical study in accordance with the design outlined in this protocol and to abide by all provisions of this protocol.

Typed Name:
Title:

Date

DOCUMENT HISTORY

Document	Date of Issue	Overall Rationale
Original Protocol	29-AUG-2022	Not applicable

Table of Contents

DOCUMENT HISTORY	3
1 PROTOCOL SUMMARY	11
1.1 Synopsis.....	11
1.2 Schema	16
1.3 Schedule of Activities	17
2 INTRODUCTION.....	19
2.1 Study Rationale	19
2.2 Background	19
2.2.1 Pharmaceutical and Therapeutic Background	19
2.2.2 Information on Other Study-related Therapy	21
2.2.2.1 PPSV23	21
2.3 Benefit/Risk Assessment.....	21
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS	22
4 STUDY DESIGN.....	26
4.1 Overall Design	26
4.2 Scientific Rationale for Study Design.....	26
4.2.1 Rationale for Endpoints	26
4.2.1.1 Immunogenicity Endpoints.....	26
4.2.1.2 Safety Endpoints	27
4.2.1.3 Future Biomedical Research	27
4.2.2 Rationale for the Use of Comparator	28
4.3 Justification for Dose	28
4.4 Beginning and End-of-Study Definition	28
4.4.1 Clinical Criteria for Early Study Termination	28
5 STUDY POPULATION	29
5.1 Inclusion Criteria	29
5.2 Exclusion Criteria	30
5.3 Lifestyle Considerations	32
5.4 Screen Failures	32
5.5 Participant Replacement Strategy.....	32
6 STUDY INTERVENTION.....	32
6.1 Study Intervention(s) Administered.....	32
6.1.1 Medical Devices.....	34
6.2 Preparation/Handling/Storage/Accountability	34
6.2.1 Dose Preparation.....	34

6.2.2	Handling, Storage, and Accountability	34
6.3	Measures to Minimize Bias: Randomization and Blinding.....	35
6.3.1	Intervention Assignment	35
6.3.2	Stratification.....	35
6.3.3	Blinding.....	35
6.4	Study Intervention Compliance.....	36
6.5	Concomitant Therapy.....	36
6.5.1	Rescue Medications and Supportive Care	36
6.6	Dose Modification (Escalation/Titration/Other).....	36
6.7	Intervention After the End of the Study	36
6.8	Clinical Supplies Disclosure	37
6.9	Standard Policies.....	37
7	DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT WITHDRAWAL	37
7.1	Discontinuation of Study Intervention.....	37
7.2	Participant Withdrawal From the Study.....	37
7.3	Lost to Follow-up	38
8	STUDY ASSESSMENTS AND PROCEDURES	38
8.1	Administrative and General Procedures	39
8.1.1	Informed Consent.....	39
8.1.1.1	General Informed Consent.....	39
8.1.1.2	Consent and Collection of Specimens for Future Biomedical Research	40
8.1.2	Inclusion/Exclusion Criteria	40
8.1.3	Participant Identification Card.....	40
8.1.4	Medical History	40
8.1.5	Prior and Concomitant Medications Review	40
8.1.5.1	Prior Medications.....	40
8.1.5.2	Concomitant Medications	41
8.1.6	Assignment of Screening Number	41
8.1.7	Assignment of Treatment/Randomization Number	41
8.1.8	Study Intervention Administration	41
8.1.8.1	Timing of Dose Administration	42
8.1.9	Electronic Vaccination Report Card	42
8.1.10	Discontinuation and Withdrawal	42
8.1.10.1	Withdrawal From Future Biomedical Research	43
8.1.11	Participant Blinding/Unblinding.....	43
8.1.12	Calibration of Equipment.....	44
8.2	Immunogenicity Assessments	44

8.2.1	Multiplex Opsonophagocytic Assay	45
8.2.2	Pneumococcal Electrochemiluminescence Assay	45
8.3	Safety Assessments.....	45
8.3.1	Physical Examinations	45
8.3.2	Pregnancy Testing.....	46
8.3.3	Body Temperature Measurement.....	46
8.3.4	Postvaccination Observation Period	46
8.3.5	Clinical Safety Laboratory Assessments	46
8.4	Adverse Events, Serious Adverse Events, and Other Reportable Safety Events	47
8.4.1	Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safety Event Information	47
8.4.2	Method of Detecting AEs, SAEs, and Other Reportable Safety Events.....	49
8.4.3	Follow-up of AE, SAE, and Other Reportable Safety Event Information...	49
8.4.4	Regulatory Reporting Requirements for SAE	49
8.4.5	Pregnancy and Exposure During Breastfeeding	50
8.4.6	Disease-related Events and/or Disease-related Outcomes Not Qualifying as AEs or SAEs	50
8.4.7	Events of Clinical Interest.....	50
8.4.8	Adverse Events on the VRC	50
8.4.8.1	Solicited Adverse Event.....	50
8.4.8.2	Unsolicited Adverse Events	51
8.5	Treatment of Overdose.....	51
8.6	Pharmacokinetics.....	51
8.7	Pharmacodynamics.....	51
8.8	Biomarkers	51
8.9	Future Biomedical Research Sample Collection.....	51
8.10	Medical Resource Utilization and Health Economics.....	51
8.11	Visit Requirements.....	52
8.11.1	Screening.....	52
8.11.2	Treatment Period/Vaccination Visit	52
9	STATISTICAL ANALYSIS PLAN	52
9.1	Statistical Analysis Plan Summary.....	52
9.2	Responsibility for Analyses/In-house Blinding	54
9.3	Hypotheses/Estimation	54
9.4	Analysis Endpoints.....	54
9.4.1	Immunogenicity Endpoints	54
9.4.2	Safety Endpoints	55
9.5	Analysis Populations.....	56

9.5.1	Immunogenicity Analysis Populations	56
9.5.2	Safety Analysis Populations	56
9.6	Statistical Methods.....	57
9.6.1	Statistical Methods for Immunogenicity Analyses	57
9.6.2	Statistical Methods for Safety Analyses	60
9.6.2.1	Overall Safety Assessment	60
9.6.3	Demographic and Baseline Characteristics	61
9.7	Interim Analyses	62
9.8	Multiplicity	62
9.9	Sample Size and Power Calculations	62
9.9.1	Sample Size and Power for Immunogenicity Analyses	62
9.9.2	Sample Size and Power for Safety Analyses	63
9.10	Subgroup Analyses.....	64
9.11	Compliance (Medication Adherence).....	64
9.12	Extent of Exposure.....	64
10	SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS	65
10.1	Appendix 1: Regulatory, Ethical, and Study Oversight Considerations	65
10.1.1	Code of Conduct for Clinical Trials.....	65
10.1.2	Financial Disclosure.....	67
10.1.3	Data Protection.....	68
10.1.3.1	Confidentiality of Data	68
10.1.3.2	Confidentiality of Participant Records.....	68
10.1.3.3	Confidentiality of IRB/IEC Information.....	68
10.1.4	Publication Policy	69
10.1.5	Compliance with Study Registration and Results Posting Requirements ...	69
10.1.6	Compliance with Law, Audit, and Debarment	69
10.1.7	Data Quality Assurance	70
10.1.8	Source Documents	71
10.1.9	Study and Site Closure.....	71
10.2	Appendix 2: Clinical Laboratory Tests.....	72
10.3	Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting.....	73
10.3.1	Definitions of Medication Error, Misuse, and Abuse	73
10.3.2	Definition of AE	73
10.3.3	Definition of SAE	75
10.3.4	Additional Events Reported.....	76
10.3.5	Recording AE and SAE	76

10.3.6	Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor	81
10.4	Appendix 4: Medical Device and Drug-device Combination Products: Product Quality Complaints/Malfunctions: Definitions, Recording, and Follow-up	82
10.4.1	Definitions.....	82
10.4.2	Medical Device/Combination Medicinal Products – Documenting and Reporting.....	82
10.4.3	Recording, Assessing Causality, and Follow-up of Adverse Events due to Malfunctions (serious and nonserious)	83
10.5	Appendix 5: Contraceptive Guidance.....	84
10.5.1	Definitions.....	84
10.5.2	Contraception Requirements.....	85
10.6	Appendix 6: Collection and Management of Specimens for Future Biomedical Research.....	86
10.7	Appendix 7: Country-specific Requirements	91
10.8	Appendix 8: Abbreviations	92
11	REFERENCES.....	94

LIST OF TABLES

Table 1	Study Interventions	33
Table 2	Approximate Blood Volumes Drawn by Study Visit and by Sample Type	39
Table 3	Reporting Time Periods and Time Frames for Adverse Events and Other Reportable Safety Events	48
Table 4	Solicited Adverse Events	51
Table 5	Analysis Strategy for Immunogenicity Variables	59
Table 6	Analysis Strategy for Safety Parameters	61
Table 7	Assumption of OPA GMT ratio (V116/PPSV23) and power for each of the 12 common serotypes, the cross-reactive serotype 15B, and the unique serotype 15C with 440 participants	62
Table 8	Assumption of the proportion of participants with a ≥ 4 -fold rise from baseline OPA responses and power for each of the 8 unique serotypes (excluding 15C) with 440 participants	63
Table 9	Differences in Incidence of Adverse Event Rates Between the 2 Vaccination Groups That Can be Detected With an Approximately 80% Probability	64
Table 10	Protocol-required Safety Laboratory Assessments	72

LIST OF FIGURES

Figure 1 V116-009 Study Design.....16

1 PROTOCOL SUMMARY

1.1 Synopsis

Protocol Title: A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Japanese Adults 65 Years of Age or Older

Short Title: Safety and immunogenicity of V116 in vaccine-naïve Japanese older adults

Acronym: STRIDE-9

Hypotheses, Objectives, and Endpoints:

Hypotheses are aligned with objectives in the Objectives and Endpoints table.

Objectives and endpoints will be evaluated in pneumococcal vaccine-naïve Japanese adults ≥ 65 years of age who are administered a single dose of V116 or PPSV23. For the objectives in this study, the V116 serotypes are categorized as:

- 12 common serotypes in V116 and PPSV23 (3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20, 22F, and 33F).
- 9 unique serotypes in V116 (6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B).
- 2 cross-reactive serotypes in V116 (6C, 15B)

Objectives	Endpoints
Primary	
<ul style="list-style-type: none">• Objective: To evaluate the safety and tolerability of V116 as assessed by the proportion of participants with adverse events (AEs).	<ul style="list-style-type: none">• Solicited injection-site AEs from Day 1 through Day 5 postvaccination• Solicited systemic AEs from Day 1 through Day 5 postvaccination• Vaccine-related Serious Adverse Events (SAEs) from Day 1 through the duration of participation in the study

Objectives	Endpoints
<ul style="list-style-type: none"> • Objective: To compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 days postvaccination with V116 versus PPSV23 for the 12 common serotypes in V116 and PPSV23, the cross-reactive serotype 15B in V116, and the unique serotype 15C in V116. <p>Hypothesis (H1): V116 is noninferior to PPSV23 as assessed by serotype-specific OPA GMTs at 30 days postvaccination for the 12 common serotypes in V116 and PPSV23.</p> <p>(The statistical criterion for noninferiority requires the lower bound of the 2-sided 95% confidence interval [CI] of the OPA GMT ratio [V116/PPSV23] to be >0.5.)</p> <p>Hypothesis (H2): V116 is noninferior to PPSV23 as assessed by serotype-specific OPA GMTs at 30 days postvaccination for 15B, the cross-reactive serotype in V116 and contained in PPSV23.</p> <p>(The statistical criterion for noninferiority requires the lower bound of the 2-sided 95% CI of the OPA GMT ratio [V116/PPSV23] to be >0.5.)</p> <p>Hypothesis (H3): V116 is superior to PPSV23 as assessed by serotype-specific OPA GMTs at 30 days postvaccination for the unique serotype 15C in V116.</p> <p>(The statistical criterion for superiority requires the lower bound of the 2-sided 95% CI of the OPA GMT ratio [V116/PPSV23] to be >1.0.)</p>	<ul style="list-style-type: none"> • Serotype-specific OPA responses

Objectives	Endpoints
<ul style="list-style-type: none"> • Objective: To compare the proportions of participants with a ≥ 4 fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination with V116 versus PPSV23 for the 8 unique serotypes in V116 (except for serotype 15C). • Hypothesis (H4): V116 is superior to PPSV23 as assessed by the proportions of participants with a ≥ 4 fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination for the 8 unique serotypes in V116 (except for serotype 15C). (The statistical criterion for superiority requires the lower bound of the 2 sided 95% CI of the differences [V116 – PPSV23] between the proportions of participants with a ≥ 4 fold rise from baseline to 30 days postvaccination to be >0.) 	<ul style="list-style-type: none"> • Serotype-specific OPA responses
Secondary	
<ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific OPA GMTs at 30 days postvaccination with V116 compared with PPSV23 for the 8 unique serotypes in V116 (except for serotype 15C) and the cross-reactive serotype 6C in V116. 	<ul style="list-style-type: none"> • Serotype-specific OPA responses
<ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 30 days postvaccination with V116 compared with PPSV23 for the 12 common serotypes in V116 and PPSV23 and the 9 unique serotypes in V116. 	<ul style="list-style-type: none"> • Serotype-specific IgG responses
<ul style="list-style-type: none"> • Objective: To evaluate the proportions of participants with a ≥ 4 fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination with V116 versus PPSV23 for the 12 common serotypes in V116 and PPSV23, the unique serotype 15C in V116, and the 2 cross-reactive serotypes in V116. 	<ul style="list-style-type: none"> • Serotype-specific OPA responses

Objectives	Endpoints
<ul style="list-style-type: none"> Objective: To evaluate the proportions of participants with a ≥ 4-fold rise in serotype-specific IgG responses from baseline to 30 days postvaccination with V116 and separately for PPSV23, for the 12 common serotypes in V116 and the 9 unique serotypes in V116. 	<ul style="list-style-type: none"> Serotype-specific IgG responses
<ul style="list-style-type: none"> Objective: To evaluate the serotype-specific geometric mean fold rise (GMFR) in serotype-specific OPA and IgG responses from baseline to 30 days postvaccination with V116 and separately for PPSV23, for the 12 common serotypes in V116 and the 9 unique serotypes in V116. 	<ul style="list-style-type: none"> Serotype-specific OPA and IgG responses

Overall Design:

Study Phase	Phase 3
Primary Purpose	Prevention
Indication	Pneumococcal disease
Population	Japanese Adults ≥ 65 years of age
Study Type	Interventional
Intervention Model	Parallel This is a multi-site study.
Type of Control	Active control without placebo
Study Blinding	Double-blind with in-house blinding
Blinding Roles	Participants or Subjects Investigator Sponsor
Estimated Duration of Study	<p>The Sponsor estimates that the study will require approximately 5 months from the time the first participant (or their legally acceptable representative) provides documented informed consent until the last participant's last study-related contact.</p> <p>For purposes of analysis and reporting, the overall study ends when the Sponsor receives the last laboratory result or at the time of final contact with the last participant, whichever comes last.</p>

Number of Participants:

Approximately 440 participants will be randomized, with approximately 220 in each intervention group, as described in Section 9.9.

Intervention Groups and Duration:

Intervention Groups	Intervention Group Name	Vaccine	Dose Strength	Dose Frequency	Route of Admin	Vaccination Regimen	Use
	V116	V116	4 µg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B)	Single Dose	IM	Single Dose at Visit 1 (Day 1)	Test Product
	PPSV23	PPSV23	25 µg of each PnPs antigen (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F)	Single Dose	IM	Single Dose at Visit 1 (Day 1)	Comparator
Admin=administration; IM=intramuscular; PnPs=pneumococcal polysaccharide; PPSV23=pneumococcal vaccine, polyvalent (23-valent); V116=pneumococcal 21-valent conjugate vaccine. Other current or former name(s) or alias(es) for study intervention(s) are as follows: V116, polyvalent pneumococcal conjugate vaccine (pPCV).							
Total Number of Intervention Groups/ Arms	2						
Duration of Participation	Each participant will participate in the study for approximately 30 days from the time the participant provides documented informed consent through the final contact.						

Study Governance Committees:

Executive Oversight Committee	No
Data Monitoring Committee	No
Clinical Adjudication Committee	No
Study governance considerations are outlined in Appendix 1.	


Study Accepts Healthy Volunteers: Yes

A list of abbreviations is in Appendix 8.

1.2 Schema

The study design is depicted in Figure 1.

Figure 1 V116-009 Study Design



1.3 Schedule of Activities

Study Period:	Intervention and Follow-up			Notes
Visit Number:	1	2	3	
Visit Type:	Site Visit	Telephone Contact	Site Visit	
Study Day:	Day 1	Day 7	Day 30	
Visit Window:	-	Day 7 to Day 10	Day 30 to Day 44	
Administrative Procedures				
Screening Procedures				
Informed Consent	X			Must be obtained before any study procedure is conducted.
Informed Consent for FBR (optional)	X			Participation in FBR is optional and consent must be obtained before the blood sample (DNA sample) is collected.
Assignment of Screening Number	X			
Inclusion/Exclusion Criteria	X			
Medical History	X			
Postrandomization Procedures				
Assignment of Randomization Number	X			
Participant Identification Card	X			
Prior/Concomitant Medication and Nonstudy Vaccination Review	X	X	X	
V116 or PPSV23 Administration (Blinded)	X			
Provide Electronic Device or Configure Participant's Own Electronic Device for eVRC Data Collection	X			
Review eVRC Data With Participant		X	X	
Collect Electronic Device From Participants Who Received an Electronic Device			X	
Safety Procedures				
Complete Physical Examination	X			Performed by investigator or medically qualified designee at screening and before vaccination.
Pregnancy Test (if applicable)	X			Participants of Childbearing Potential (POCBP) must have a negative urine or serum test (sensitive to ≤ 25 IU hCG) result before vaccination.

Study Period:	Intervention and Follow-up			Notes
Visit Number:	1	2	3	
Visit Type:	Site Visit	Telephone Contact	Site Visit	
Study Day:	Day 1	Day 7	Day 30	
Visit Window:	-	Day 7 to Day 10	Day 30 to Day 44	
Body Temperature Measurement	X			Measured before vaccination. Participants with febrile illness within 72 hours before vaccination must be rescheduled.
Postvaccination Observation Period	X			Observed by blinded study-site personnel for at least 30 minutes postvaccination.
AE Monitoring	X	X	X	Nonserious AEs collected Day 1 through Day 30 postvaccination. SAEs, deaths and malfunction which may lead to SAEs incidents collected from the time consent is provided through duration of study participation.
Immunogenicity Procedures				
Serum for Immunogenicity Assays	X		X	Visit 1 sample should be collected before vaccination.
Future Biomedical Research				
Blood (DNA) for FBR	X			For participants who provided FBR consent. Should be collected before vaccination at Visit 1, or at a later date as long as the FBR consent is obtained prior to collection.
AE=adverse event; DNA=deoxyribonucleic acid; eVRC=electronic vaccination report card; FBR=future biomedical research; hCG=human chorionic gonadotropin; IU=international units; PPSV23= pneumococcal vaccine, polyvalent (23-valent); SAE=serious adverse event.				

2 INTRODUCTION

The Sponsor is developing an investigational polyvalent pneumococcal 21-valent conjugate vaccine (V116) for the prevention of pneumococcal disease caused by the serotypes in the vaccine.

2.1 Study Rationale

Pneumococcal disease caused by *Streptococcus pneumoniae* is associated with significant morbidity and mortality worldwide. The population of adults ≥ 65 years of age is at elevated risk for pneumococcal disease due to age-related physiological changes in the respiratory system and a high prevalence of other medical conditions associated with increased risk for pneumococcal disease [Drijkoningen, J. J 2014] [Janssens, J. P. 2004] [Sunagawa, T., et al 2018].

Introduction of PCV13 into the pediatric National Immunization Program (NIP) resulted in a decrease in invasive pneumococcal disease (IPD) in children caused by the serotypes contained in PCV13. Although a similar but indirect effect of pediatric vaccination is experienced in adults, an unmet medical need exists due to increases in IPD caused by serotypes not included in licensed PCVs in adults, especially in older adults.

V116 is an investigational PCV designed to address this unmet medical need and includes *S pneumoniae* serotypes not included in licensed PCVs, which account for the majority of IPD observed in adults.

This Phase 3 clinical study is designed to evaluate the safety, tolerability, and immunogenicity of V116 compared with PPSV23 in pneumococcal vaccine-naïve Japanese adults ≥ 65 years of age.

2.2 Background

To date, a Phase 1/2 study (V116-001) in the US and a Phase 1 study in Japan (V116-002) have been conducted with V116. Results from the Phase 1 part of V116 001 were used to select the optimal vaccine formulation for subsequent development. Results from V116-002 showed that V116 was well tolerated and with a safety profile comparable to PPSV23 in Japanese adults. Results from both studies showed that V116 is immunogenic and has acceptable safety and tolerability in healthy adults. Refer to the IB for detailed background information on V116.

2.2.1 Pharmaceutical and Therapeutic Background

In children and adults, infection with *S pneumonia* can result in pneumonia, otitis media, sinusitis and IPD. IPD may also be accompanied by meningitis or pneumonia. *S pneumoniae* accounts for approximately 20% of the causative bacteria in community-onset pneumonia (community-acquired and hospital-acquired pneumonia) in adults [National Institute of Infectious Diseases 2018].

Many countries have incorporated licensed PCVs (e.g., Prevnar 13™) into their infant immunization programs. In Japan, Prevnar™ was covered by the emergency promotion fund project for vaccination initiated in November 2010 and introduced into the NIP for pediatrics in April 2013. Prevnar™ was replaced by Prevnar 13™ in November 2013. Since the overall burden of IPD in children caused by vaccine serotypes was decreased by 97% as of 2017. PCV vaccination of children under NIP has led to indirect protection in unvaccinated children and adults.

The 2014 addition of PPSV23 to the adult NIP has resulted in a decrease in adult IPD caused by the serotypes contained in the vaccine [Shimbashi, R., et al 2020]. However, the 2020 Surveillance for Invasive Bacterial Infections in Adults reported that IPD in adults caused by serotypes included in PCV13 and PPSV23 still account for approximately 27% and 54% of cases, respectively. Adult IPD caused by serotypes 3 and 19A (included in PCV13/PPSV23) and serotypes 10A, 11A, 12F, and 22F (included in PPSV23) still occurs [Epidemiological Information of Invasive Pneumococcal Infection in Children and Adults 2020]. Additionally, IPD due to serotypes not included in the licensed pneumococcal vaccines has been increasing over time.

This residual burden of disease in adults reflects the difference in serotype distribution in adults compared with infants and children. Importantly, infant vaccination with PCVs has led to an increasing incidence of disease due to serotypes not included in the licensed PCVs, particularly in adults [Ubukata, K., et al 2018] [Sando, E., et al 2019] [Miller, Elizabeth, et al 2011] [Moore, M. R., et al 2015] [Pilishvili, T. 2015] [van der Linden, M., et al 2015] [Golden, A. R., et al 2016]. Due to the limited serotype coverage of the currently licensed pneumococcal vaccines in Japan, serotype replacement by non-vaccine serotypes is being observed and may decrease the potential benefit of vaccination with currently available PCVs in the elderly.

To address this unmet medical need, serotypes were selected for inclusion in V116 based on available global epidemiology data with a primary focus on data from the elderly (≥65 years of age) in the US and EU. Based on 2018 surveillance data in US adults ≥65 years of age, the serotypes selected for inclusion in V116 account for approximately 83% of all cases of IPD, 25% to 30% of which are accounted for by the serotypes unique to V116 (US Centers for Disease Control and Prevention ABC unpublished data 2014 to 2018) [Centre for Disease Control and Prevention 2018]. In Japanese adults, data from 2020 support that the serotypes selected for inclusion in V116 account for approximately 76% of all cases of IPD, approximately 31% of which are accounted for by the serotypes unique to V116, and approximately 2% of which are accounted for by the serotype 6C and 15B, for which cross-reactive immune responses may be induced by the serotypes contained in V116 [Epidemiological Information of Invasive Pneumococcal Infection in Children and Adults 2020].

With the above considerations in mind, V116 is designed to target serotypes that account for the majority of IPD in adults including serotypes not currently contained in any licensed pneumococcal vaccine, as well as addressing the influence of serotype replacement of circulating strains, thereby addressing the unmet medical need of residual pneumococcal disease in adults. V116 is being developed to support an indication for active immunization

for the prevention of IPD and pneumococcal pneumonia caused by *S pneumoniae* serotypes 3, 6A, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in adults. In addition to the serotypes contained in V116, serotypes 6C and 15B, for which cross-reactive immune response may be induced by the serotypes contained in V116, are also evaluated. Serotype 15C represents deOAc15B contained in V116 as deOAc15B has a similar molecular structure to serotype 15C and is an active ingredient for the prevention of pneumococcal disease caused by serotype 15C.

2.2.2 Information on Other Study-related Therapy

2.2.2.1 PPSV23

The label name of PPSV23 in Japan is PNEUMOVAX® NP.

Refer to approved labeling for detailed background information on PPSV23.

PPSV23 is comprised of the polysaccharides from 23 of the serotypes causing pneumococcal disease in adults (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). The formulation is not adjuvanted and no carrier protein is used.

PPSV23 was first approved in the US in 1983 and is now licensed in more than 90 countries worldwide, including Japan.

PPSV23 is indicated for the prevention of pneumococcal disease in the population who are at least 2 years of age and at high risk of developing severe pneumococcal infections in Japan. Additionally, PNEUMOVAX®NP (PNEUMOVAX™23) is the only pneumococcal vaccine currently included in the NIP for adults in Japan and is recommended for a) adults 65 years of age or older, and b) adults 60 to under 65 years old who have cardiac, renal, or respiratory dysfunction that severely limits their own daily living activities, or have immunodeficiency that makes daily living almost impossible by HIV infection.

PPSV23 to be used in this study is approved for marketing in US.

2.3 Benefit/Risk Assessment

It cannot be guaranteed that participants in clinical studies will directly benefit from treatment during participation, as clinical studies are designed to provide information about the safety and effectiveness of an investigational medicine.

Despite the public health impact of currently available pneumococcal vaccines, pneumococcal disease in adults remains a significant unmet medical need. *S pneumoniae* is a major cause of vaccine-preventable disease worldwide, resulting in considerable morbidity and mortality [Troeger, C., et al 2018].

Vaccination with PCVs has reduced the incidence of disease caused by vaccine serotypes in pediatric population and has had an indirect effect in other age groups. However, infant vaccination with PCVs has also led to increases in IPD due to serotypes not included in the

licensed PCVs, particularly in older adults. This has resulted in an unmet medical need in this population.

V116 is designed to provide significantly broader pneumococcal disease coverage in adults as compared to currently licensed pneumococcal vaccines and is anticipated to have a generally comparable safety profile. No clinically important safety findings have been identified to date based on data from early phase clinical studies with V116.

The benefit risk profile for V116 supports continued evaluation.

Approximately 50% of participants will receive PPSV23, a vaccine indicated for the prevention of pneumococcal disease that is licensed in Japan. PPSV23 contains 23 serotypes, 12 of which are common to V116 and 11 of which are not included in V116 (PPSV23 unique serotypes). V116 is expected to provide comparable immune responses to PPSV23 for the 12 common serotypes while providing additional coverage for the 9 serotypes unique to V116. It is unknown if the investigational V116 will have the same clinical benefit as PPSV23.

Additional details regarding specific benefits and risks for participants participating in this clinical study may be found in the accompanying IB and informed consent documents.

3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS

Hypotheses are aligned with objectives in the Objectives and Endpoints table.

Objectives and endpoints will be evaluated in pneumococcal vaccine-naïve Japanese adults ≥ 65 years of age who are administered a single dose of V116 or PPSV23. For the objectives in this study, the V116 serotypes are categorized as:

- 12 common serotypes in V116 and PPSV23 (3, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20, 22F, and 33F).
- 9 unique serotypes in V116 (6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B).
- 2 cross-reactive serotypes in V116 (6C, 15B)

Objectives	Endpoints
Primary	
<ul style="list-style-type: none">• Objective: To evaluate the safety and tolerability of V116 as assessed by the proportion of participants with adverse events (AEs).	<ul style="list-style-type: none">• Solicited injection-site AEs from Day 1 through Day 5 postvaccination• Solicited systemic AEs from Day 1 through Day 5 postvaccination• Vaccine-related Serious Adverse Events (SAEs) from Day 1 through the duration of participation in the study

Objectives	Endpoints
<ul style="list-style-type: none"> Objective: To compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 days postvaccination with V116 versus PPSV23 for the 12 common serotypes in V116 and PPSV23, the cross-reactive serotype 15B in V116, and the unique serotype 15C in V116. <p>Hypothesis (H1): V116 is noninferior to PPSV23 as assessed by serotype-specific OPA GMTs at 30 days postvaccination for the 12 common serotypes in V116 and PPSV23.</p> <p>(The statistical criterion for noninferiority requires the lower bound of the 2-sided 95% confidence interval [CI] of the OPA GMT ratio [V116/PPSV23] to be >0.5.)</p> <p>Hypothesis (H2): V116 is noninferior to PPSV23 as assessed by serotype-specific OPA GMTs at 30 days postvaccination for 15B, the cross-reactive serotype in V116 and contained in PPSV23.</p> <p>(The statistical criterion for noninferiority requires the lower bound of the 2-sided 95% CI of the OPA GMT ratio [V116/PPSV23] to be >0.5.)</p> <p>Hypothesis (H3): V116 is superior to PPSV23 as assessed by serotype-specific OPA GMTs at 30 days postvaccination for the unique serotype 15C in V116.</p> <p>(The statistical criterion for superiority requires the lower bound of the 2-sided 95% CI of the OPA GMT ratio [V116/PPSV23] to be >1.0.)</p>	<ul style="list-style-type: none"> Serotype-specific OPA responses

Objectives	Endpoints
<ul style="list-style-type: none"> Objective: To compare the proportions of participants with a ≥ 4 fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination with V116 versus PPSV23 for the 8 unique serotypes in V116 (except for serotype 15C). <p>Hypothesis (H4): V116 is superior to PPSV23 as assessed by the proportions of participants with a ≥ 4 fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination for the 8 unique serotypes in V116 (except for serotype 15C).</p> <p>(The statistical criterion for superiority requires the lower bound of the 2 sided 95% CI of the differences [V116 – PPSV23] between the proportions of participants with a ≥ 4 fold rise from baseline to 30 days postvaccination to be >0.)</p>	<ul style="list-style-type: none"> Serotype-specific OPA responses
Secondary	
<ul style="list-style-type: none"> Objective: To evaluate the serotype-specific OPA GMTs at 30 days postvaccination with V116 compared with PPSV23 for the 8 unique serotypes in V116 (except for serotype 15C) and the cross-reactive serotype 6C in V116. 	<ul style="list-style-type: none"> Serotype-specific OPA responses
<ul style="list-style-type: none"> Objective: To evaluate the serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 30 days postvaccination with V116 compared with PPSV23 for the 12 common serotypes in V116 and PPSV23 and the 9 unique serotypes in V116. 	<ul style="list-style-type: none"> Serotype-specific IgG responses

Objectives	Endpoints
<ul style="list-style-type: none"> Objective: To evaluate the proportions of participants with a ≥ 4 fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination with V116 versus PPSV23 for the 12 common serotypes in V116 and PPSV23, the unique serotype 15C in V116, and the 2 cross-reactive serotypes in V116. 	<ul style="list-style-type: none"> Serotype-specific OPA responses
<ul style="list-style-type: none"> Objective: To evaluate the proportions of participants with a ≥ 4-fold rise in serotype-specific IgG responses from baseline to 30 days postvaccination with V116 and separately for PPSV23, for the 12 common serotypes in V116 and the 9 unique serotypes in V116. 	<ul style="list-style-type: none"> Serotype-specific IgG responses
<ul style="list-style-type: none"> Objective: To evaluate the serotype-specific geometric mean fold rise (GMFR) in serotype-specific OPA and IgG responses from baseline to 30 days postvaccination with V116 and separately for PPSV23, for the 12 common serotypes in V116 and the 9 unique serotypes in V116. 	<ul style="list-style-type: none"> Serotype-specific OPA and IgG responses
Exploratory	
<ul style="list-style-type: none"> Objective: To evaluate the serotype-specific IgG GMCs at 30 days postvaccination with V116 and the proportions of participants with a ≥ 4 fold rise in serotype-specific IgG responses from baseline to 30 days postvaccination with V116 for the 2 cross reactive serotypes in V116. 	<ul style="list-style-type: none"> Serotype-specific IgG responses
<ul style="list-style-type: none"> Objective: To evaluate the serotype-specific GMFR in serotype-specific OPA and IgG responses from baseline to 30 days postvaccination with V116 for the 2 cross-reactive serotypes in V116. 	<ul style="list-style-type: none"> Serotype-specific OPA and IgG responses

4 STUDY DESIGN

4.1 Overall Design

This is a phase 3, randomized, active comparator-controlled, parallel-group, multisite, double-blind study of V116 in pneumococcal vaccine-naïve Japanese adults ≥ 65 years of age.

Approximately 440 participants who have not previously received any pneumococcal vaccine (vaccine-naïve) will be randomized in a 1:1 ratio to receive a single dose of either V116 or PPSV23 on Visit 1 (Day 1). Randomization will be stratified by participant age at the time of randomization (65 to 74 years, 75 to 84 years, and ≥ 85 years).

An eVRC will be used by all participants to record solicited injection site AEs, solicited systemic AEs, and daily body temperature from Day 1 through Day 5 postvaccination. Unsolicited AEs will be recorded from Day 1 through Day 30 postvaccination. All participants will be provided an electronic device or have their own electronic device configured, if compatible, to complete the eVRC.

Information for SAEs and deaths, regardless of whether the events are considered to be vaccine related by the investigator, will be collected from the time consent is provided through completion of participation in the study.

Blood samples for immunogenicity assays will be drawn on Visit 1 (Day 1) and Visit 3 (30 days). Blood samples should be drawn prior to study vaccine administration at Visit 1 (Day 1).

Specific procedures to be performed during the study, including prescribed times and associated visit windows, are outlined in Section 1.3 of the SoA. Details of each procedure are provided in Section 8.

4.2 Scientific Rationale for Study Design

This study will evaluate the safety, tolerability, and immunogenicity of V116 in Japanese adults ≥ 65 years of age. The population enrolled in this study is adults ≥ 65 years of age who are at increased risk for pneumococcal disease.

4.2.1 Rationale for Endpoints

4.2.1.1 Immunogenicity Endpoints

The immunogenicity endpoints and associated statistical criteria are consistent with previous studies evaluating PCVs.

Sera from participants will be used to assess vaccine-induced, anti-PnPs, serotype-specific OPA and IgG responses using the validated MOPA and Pn ECL assay, respectively. Immunogenicity endpoints will be evaluated for all serotypes included in V116 and for cross reactive serotypes within a serogroup.

Several studies have shown a positive correlation between serotype-specific IgG antibody concentrations and OPA titers in children and adults [Centers for Disease Control and Prevention 2010] [Anttila, M., et al 1999] [Romero-Steiner, S., et al 1997]. OPA assesses levels of functional antibodies capable of opsonizing pneumococcal capsular polysaccharides for presentation to phagocytic cells for engulfment and subsequent killing, and therefore is considered an important immunologic surrogate for protection against IPD in adults. It is noted that IgG antibody concentration and OPA titer threshold values that correlate with protection in adults have not been defined; however, OPA responses are considered an accepted endpoint for the evaluation of novel pneumococcal vaccines in adults.

The primary immunogenicity endpoints in this study will be OPA responses. Serotypes common to both V116 and PPSV23, and serotype 15B, the cross-reactive serotype in V116 and contained in PPSV23, will be assessed for noninferiority, and serotypes unique to V116 will be assessed for superiority. While serotype 15C is unique to V116, the comparator in this study (PPSV23) contains serotype 15B, which may induce antibodies to serotype 15C due to structural similarities between the 2 serotypes in this serogroup.

Secondary and exploratory endpoints in this study include both OPA and IgG responses.

The OPA GMT, IgG GMC, GMFR, and proportion of participants with 4 fold rise in OPA and IgG responses are acceptable assessments used to evaluate novel PCVs.

Details on the immunogenicity endpoints evaluated in this study can be found in Section 9.4.1.

4.2.1.2 Safety Endpoints

Safety information will be collected from all participants on an eVRC. The eVRC used to record AEs during the postvaccination periods (Section 8.1.9) is structured as recommended in the final US FDA Patient-reported Outcome Guidance [U.S. Food and Drug Administration 2009].

The safety endpoints (ie, AEs and temperature) evaluated in this study are consistent with previous studies of V116 and published data from marketed PCVs. Detailed information for the safety endpoints evaluated in this study can be found in Section 9.4.2.

Definitions and reporting requirements for AEs are provided in Appendix 3.

4.2.1.3 Future Biomedical Research

The Sponsor will conduct FBR on DNA specimens for which consent was provided during this clinical study.

Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol and will only be conducted on specimens from appropriately consented participants. The objective of collecting/retaining specimens for FBR is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer,

more effective drugs/vaccines, and/or to ensure participants receive the correct dose of the correct drug/vaccine at the correct time. The details of FBR are presented in Appendix 6.

4.2.2 Rationale for the Use of Comparator

Placebo-controlled clinical studies for new PCVs are no longer practical given the proven clinical efficacy and widespread use of licensed pneumococcal vaccines worldwide.

Of the currently licensed pneumococcal vaccines, PPSV23 has the most serotypes in common with V116. Additionally, PPSV23 is the only pneumococcal vaccine currently included in the NIP for adults in Japan and is recommended for adults 65 years of age or older.

The use of PPSV23 in this study is consistent with the product labeling of PPSV23.

4.3 Justification for Dose

The V116 dose of 4 µg/each PnPs was selected based on review of safety and immunogenicity data from the Phase 1 and Phase 2 studies. In Phase 1, 2 doses of V116 were evaluated: a single dose containing 2 µg/each PnPs and a single dose of 4 µg/each PnPs. Based on the data from Phase 1, the V116 dose of 4 µg/each PnPs was selected for further evaluation in Phase 2. Results from Phase 2 showed that the V116 dose of 4 µg/each PnPs is well tolerated and generates serotype-specific immune responses. These data support the selection of the V116 dose of 4 µg/each PnPs for further development in Phase 3.

Refer to the IB for detailed background information on V116.

The dose of PPSV23 selected for use in this study is consistent with the approved Japan dosing and product labeling of PPSV23.

4.4 Beginning and End-of-Study Definition

The overall study begins when the first participant (or their legally acceptable representative) provides documented informed consent. The overall study ends when the last participant completes the last study-related contact, withdraws consent, or is lost to follow-up (ie, the participant is unable to be contacted by the investigator).

For purposes of analysis and reporting, the overall study ends when the Sponsor receives the last laboratory result or at the time of final contact with the last participant, whichever comes last.

4.4.1 Clinical Criteria for Early Study Termination

The clinical study may be terminated early if the extent (incidence and/or severity) of emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population as a whole is unacceptable. In addition, further recruitment in the study or at (a) particular study site(s) may be stopped due to insufficient compliance with the protocol, GCP, and/or

other applicable regulatory requirements, procedure-related problems or the number of discontinuations for administrative reasons is too high.

5 STUDY POPULATION

As stated in the Code of Conduct for Clinical Trials (Appendix 1.1), this study includes participants of varying age (as applicable), race, ethnicity, and sex (as applicable). The collection and use of these demographic data will follow all local laws and participant confidentiality guidelines while supporting the study of the disease, its related factors, and the IMP under investigation.

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

5.1 Inclusion Criteria

A participant is eligible for inclusion in the study if the participant meets all of the following criteria:

Type of Participant and Disease Characteristics

1. The participant may have underlying chronic conditions if the conditions are assessed to be stable as per the investigator's judgment.

Demographics

2. Is Japanese of any sex/gender, ≥ 65 years of age, at the time of informed consent.

Participants Assigned Female Sex at Birth

3. A participant assigned female sex at birth is eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies:
 - Is not a POCBP
 - OR
 - Is a POCBP and:
 - Uses an acceptable contraceptive method or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), as described in Appendix 5 during the intervention period and for at least 30 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention. Contraceptive use by POCBPs should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception

requirements in the local label for any of the study interventions are more stringent than the requirements above, the local label requirements are to be followed.

- Has a negative highly sensitive pregnancy test (urine or serum) within 24 hours (for urine test) or 72 hours (for serum test) before the first dose of study intervention. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. Additional requirements for pregnancy testing during and after study intervention are in Section 8.3.2.
- Medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.

Informed Consent

4. The participant has provided documented informed consent for the study. The participant may also provide documented informed consent for FBR. However, the participant may be enrolled in the study without providing consent for FBR.

Additional Categories

5. The participant has the ability to complete eVRC data collection without assistance based on judgment of the investigator.

5.2 Exclusion Criteria

The participant must be excluded from the study if the participant meets any of the following criteria:

Medical Conditions

1. Has a history of IPD (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
2. Has a known hypersensitivity to any component of V116 or PPSV23, including diphtheria toxoid.
3. Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented HIV infection, functional or anatomic asplenia, or history of autoimmune disease.
4. Has a coagulation disorder contraindicating intramuscular vaccination.
5. *Had a recent febrile illness (defined as oral or tympanic temperature $\geq 38.0^{\circ}\text{C}$; axillary or temporal temperature $\geq 37.4^{\circ}\text{C}$) or received antibiotic therapy for any acute illness occurring < 72 hours before receipt of study vaccine.

6. Has a known malignancy that is progressing or has required active treatment <3 years before enrollment. **Note:** Participants with basal cell and/or squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.

Prior/Concomitant Therapy

7. Received prior administration of any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside of the protocol.
8. *Received systemic corticosteroids (prednisone equivalent of ≥ 20 mg/day) for ≥ 14 consecutive days and has not completed intervention ≥ 14 days before receipt of study vaccine. **Note:** Physiologic replacement doses (prednisone equivalent of approximately 5 mg/day), topical, ophthalmic, intraarticular or soft-tissue (eg, bursa, tendon steroid injections), and inhaled/nebulized steroids are permitted.
9. Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
10. *Received any nonlive vaccine ≤ 14 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine ≤ 30 days after receipt of any study vaccine.

Exception: Inactivated influenza vaccine may be administered but must be given ≥ 7 days before or ≥ 15 days after receipt of study vaccine. SARS-CoV-2 mRNA or protein subunit vaccines may be administered but must be given ≥ 14 days before or ≥ 15 days after receipt of study vaccine. SARS-CoV-2 vaccines other than mRNA and protein subunit vaccines are not eligible for this exception and are subject to requirements of exclusion criteria 10 and 11.

11. *Received any live virus vaccine ≤ 30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤ 30 days after receipt of study vaccine.
12. Received a blood transfusion or blood products, including immunoglobulin ≤ 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the Day 30 postvaccination blood draw is complete. Autologous blood transfusions are not considered an exclusion criterion.

Prior/Concurrent Clinical Study Experience

13. Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.

Diagnostic Assessments

Not Applicable

Other Exclusions

14. In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
15. Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
16. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.

For items with an asterisk (*), if the participant meets these exclusion criteria, Visit 1 may be rescheduled for a time when these criteria are not met.

5.3 Lifestyle Considerations

No lifestyle restrictions are required.

5.4 Screen Failures

Screen failures are defined as participants who consent to participate in the clinical study, but are not subsequently randomized in the study. A minimal set of screen-failure information is required to ensure transparent reporting of screen-failure participants to meet the CONSORT publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen-failure details, eligibility criteria, and any AEs or SAEs meeting reporting requirements as outlined in the data entry guidelines.

5.5 Participant Replacement Strategy

A participant who withdraws from the study will not be replaced.

6 STUDY INTERVENTION

Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.

Clinical supplies (V116 and PPSV23) will be packaged to support enrollment. Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.

6.1 Study Intervention(s) Administered

The study interventions to be used in this study are outlined in [Table 1](#).

Table 1 Study Interventions

Arm Name	Arm Type	Intervention Name	Intervention Type	Dose Formulation	Unit Dose Strength(s)	Dosage Level(s)	Route of Admin.	Vaccination Regimen	Use	IMP or NIMP/AxMP	Sourcing
V116	Experimental	Pneumococcal 21-valent conjugate vaccine	Biological/Vaccine	Sterile Solution (Prefilled Syringe)	4 µg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B)	0.5 mL	IM	Single Dose at Visit 1 (Day 1)	Test Product	IMP	Central
PPSV23	Active Comparator	Pneumococcal Vaccine, Polyvalent (23-valent)	Biological/Vaccine	Sterile Solution (Prefilled Syringe)	25 µg of each PnPs antigen (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F)	0.5 mL	IM	Single Dose at Visit 1 (Day 1)	Comparator	IMP	Central
<p>Admin=administration; IM=intramuscular; IMP=investigational medicinal product; NIMP/AxMP=non-investigational/auxiliary medicinal product; PnPs=pneumococcal polysaccharide; PPSV23=pneumococcal vaccine, polyvalent (23-valent); V116=pneumococcal 21-valent conjugate vaccine.</p> <p>The classification of IMP and NIMP/AxMP in this table is based on guidance issued by the European Commission and applies to countries in the European Economic Area. Country differences with respect to the definition/classification of IMP and NIMP/AxMP may exist. In these circumstances, local legislation is followed.</p>											

All supplies indicated in [Table 1](#) will be provided per the “Sourcing” column depending on local country operational requirements. If local sourcing, every attempt should be made to source these supplies from a single lot/batch number.

Refer to Section 8.1.8 for details regarding administration of the study intervention.

6.1.1 Medical Devices

Combination Medicinal Product(s) (MSD marketed/MSD investigation medicinal product and medical device or nonMSD marketed/nonMSD investigational product and medical device) provided for use in this study are V116 and PPSV23, a single-dose prefilled syringe. Refer to Appendix 4 for instruction on reporting events associated with these combination medicinal products.

6.2 Preparation/Handling/Storage/Accountability

6.2.1 Dose Preparation

There are no specific calculations or evaluations required to be performed to administer the proper dose to each participant. The rationale for selection of doses to be used in this study is in Section 4.3.

Specific procedures that are required for dose preparation are outlined in the Investigator Trial File Binder.

As detailed in Section 6.3.3, study vaccines will be prepared by an unblinded member of the study-site staff.

6.2.2 Handling, Storage, and Accountability

The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study intervention received, and any discrepancies are reported and resolved before use of the study intervention.

Only participants enrolled in the study may receive study intervention, and only authorized site staff may supply or administer study intervention. All study interventions must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.

The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records).

For all study sites, the local country Sponsor personnel or designee will provide appropriate documentation that must be completed for drug accountability and return, or local discard and destruction if appropriate. Where local discard and destruction is appropriate, the

investigator is responsible for ensuring that a local discard/destruction procedure is documented.

The study site is responsible for recording the lot number, manufacturer, and expiry date for any locally purchased product (if applicable) as per local guidelines unless otherwise instructed by the Sponsor.

The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution, and usage of study interventions in accordance with the protocol and any applicable laws and regulations.

6.3 Measures to Minimize Bias: Randomization and Blinding

6.3.1 Intervention Assignment

Intervention randomization will occur centrally using an IRT system. There are 2 study intervention arms. Participants will be assigned randomly in a 1:1 ratio to receive either V116 or PPSV23.

6.3.2 Stratification

Intervention randomization will be stratified according to the following factor, since immune response decreases with age:

1. Participant age at time of randomization (65 to 74 vs. 75 to 84 vs. ≥ 85 years of age)

6.3.3 Blinding

A double-blinding technique with in-house blinding will be used. V116 and PPSV23 will be prepared and/or dispensed in a blinded fashion by an unblinded pharmacist or qualified study-site personnel. The participant, the investigator, and Sponsor personnel or delegate(s) who are involved in the study intervention administration or clinical evaluation of the participants are unaware of the intervention assignments.

Because V116 and PPSV23 have a different appearance, the unblinded pharmacist (or qualified study-site personnel) will be responsible for receiving, maintaining, preparing and/or dispensing, and administering these study vaccines (Section 8.1.8).

To avoid bias, contact between the unblinded study site personnel and study participants is strictly prohibited for any study-related procedures/assessments other than administration of study vaccines. Blinded site personnel will be responsible for all other study procedures/assessments specified in Section 1.3.

An unblinded Clinical Research Associate will monitor vaccine accountability at the study site. All other Sponsor personnel or delegate(s) directly involved with the conduct of this study will remain blinded to the participant-level intervention assignment.

See Section 8.1.11 for a description of the method of unblinding a participant during the study should such action be warranted.

6.4 Study Intervention Compliance

Given that a single dose of V116 or PPSV23 will be administered in this study, intervention compliance will not be assessed.

6.5 Concomitant Therapy

Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the ongoing study (Section 5.2). The investigator should discuss any questions regarding this with the Sponsor Clinical Director. The final decision on any supportive therapy or vaccination rests with the investigator and/or the participant's primary physician.

It is important to record the use of any analgesic or antipyretic medication that occurs on the day of vaccination on the eVRC and appropriate eCRF.

Listed below are specific restrictions for concomitant therapy or vaccination:

- Administration of a nonstudy pneumococcal vaccine is prohibited during the study.
- Nonstudy vaccines may only be administered before or after the receipt of study vaccine according to the time frames specified in the Exclusion Criteria (Section 5.2).
- Receipt of systemic corticosteroids (prednisone equivalent ≥ 20 mg/day) for ≥ 14 consecutive days is prohibited from 14 days before vaccination through 30 days following vaccination. **Note:** Physiologic replacement doses (prednisone equivalent of approximately 5 mg/day), topical, ophthalmic, intraarticular or soft-tissue (eg, bursa, tendon steroid injections), and inhaled/nebulized steroids are permitted.

Any deviation from the above requires consultation between the investigator and the Sponsor and written documentation of the collaborative decision on participant management.

Use of prior and concomitant medications/vaccinations should be recorded as described in Section 8.1.5.

6.5.1 Rescue Medications and Supportive Care

No rescue or supportive medications are specified for use in this study.

6.6 Dose Modification (Escalation/Titration/Other)

No dose modification is allowed in this study.

6.7 Intervention After the End of the Study

There is no study-specified intervention after the end of the study.

6.8 Clinical Supplies Disclosure

This study is blinded but supplies are provided as open label; therefore, an unblinded pharmacist or qualified study-site personnel will be used to blind supplies. Study intervention identity (name, strength, or potency) is included in the label text; random code/disclosure envelopes or lists are not provided.

The emergency unblinding call center will use the intervention/randomization schedule for the study to unblind participants and to unmask study intervention identity. The emergency unblinding call center should only be used in cases of emergency (see Section 8.1.11). If the emergency unblinding call center is not available for a given site in this study, the central electronic intervention randomization system (IRT) should be used to unblind participants and to unmask study intervention identity. The Sponsor will not provide random code/disclosure envelopes or lists with the clinical supplies.

See Section 8.1.11 for a description of the method of unblinding a participant during the study, should such action be warranted.

6.9 Standard Policies

Not applicable.

7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT WITHDRAWAL

7.1 Discontinuation of Study Intervention

In clinical studies with a single intervention, discontinuation of study intervention can only occur before the intervention and generally represents withdrawal from the study. Participants who receive a single-dose intervention cannot discontinue study intervention.

7.2 Participant Withdrawal From the Study

A participant must be withdrawn from the study if the participant or participant's legally acceptable representative withdraws consent from the study.

If a participant withdraws from the study, they will no longer receive study intervention or be followed at scheduled protocol visits.

Specific details regarding procedures to be performed at the time of withdrawal from the study, as well as specific details regarding withdrawal from FBR, are outlined in Section 8.1.10.1. The procedures to be performed should a participant repeatedly fail to return for scheduled visits and/or if the study site is unable to contact the participant are outlined in Section 7.3.

7.3 Lost to Follow-up

If a participant fails to return to the clinic for a required study visit and/or if the site is unable to contact the participant, the following procedures are to be performed:

- The site must attempt to contact the participant and reschedule the missed visit. If the participant is contacted, the participant should be counseled on the importance of maintaining the protocol-specified visit schedule.
- The investigator or designee must make every effort to regain contact with the participant at each missed visit (eg, telephone calls and/or a certified letter to the participant's last known mailing address or locally equivalent methods). These contact attempts should be documented in the participant's medical record.
- Note: A participant is not considered lost to follow-up until the last scheduled visit for the individual participant. The missing data for the participant will be managed via the prespecified statistical data handling and analysis guidelines.

8 STUDY ASSESSMENTS AND PROCEDURES

- Study procedures and their timing are summarized in the SoA.
- Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct.
- The investigator is responsible for ensuring that procedures are conducted by appropriately qualified (by education, training, and experience) staff. Delegation of study-site personnel responsibilities will be documented in the Investigator Trial File Binder (or equivalent).
- All study-related medical decisions must be made by an investigator who is a qualified physician.
- All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.
- Procedures conducted as part of the participant's routine clinical management (eg, blood count) and obtained before signing of ICF may be used for screening or baseline purposes provided the procedure met the protocol-specified criteria and were performed within the time frame defined in the SoA.
- Additional evaluations/testing may be deemed necessary by the investigator and or the Sponsor for reasons related to participant safety. In some cases, such evaluation/testing may be potentially sensitive in nature (eg, HIV, hepatitis C), and thus local regulations may require that additional informed consent be obtained from the participant. In these cases, such evaluations/testing will be performed in accordance with those regulations.

The maximum amount of blood collected from each participant at each visit will not exceed 40 mL, and the total amount of blood collected over the duration of the study will not exceed 70 mL (Table 2).

Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples.

Table 2 Approximate Blood Volumes Drawn by Study Visit and by Sample Type

	Visit 1	Visit 3	Total
Parameter	Approximate Blood Volume		
Immunogenicity assessment	30 mL	30 mL	60 mL
DNA for Future Biomedical Research ^a	8.5 mL	N/A	8.5 mL
Expected total	38.5 mL	30 mL	68.5 mL

N/A=not applicable.

^a Samples for future biomedical research will only be obtained from participants who provide separate consent for collection of these optional samples.

8.1 Administrative and General Procedures

8.1.1 Informed Consent

The investigator or medically qualified designee (consistent with local requirements) must obtain documented informed consent from each potential participant (or their legally acceptable representative) prior to participating in this clinical study or FBR. If there are changes to the participant's status during the study (eg, health or age of majority requirements), the investigator or medically qualified designee must ensure the appropriate documented informed consent is in place.

8.1.1.1 General Informed Consent

Informed consent given by the participant or their legally acceptable representative must be documented on a consent form. The form must include the study protocol number, study protocol title, dated signature, and agreement of the participant (or his/her legally acceptable representative) and of the person conducting the consent discussion.

A copy of the signed and dated informed consent form should be given to the participant (or their legally acceptable representative) before participation in the study.

The initial ICF, any subsequent revised ICF, and any written information provided to the participant must receive the IRB/IEC's approval/favorable opinion in advance of use. The participant or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the participant's willingness to continue participation in the study. The communication of this information will be provided and documented via a revised consent form or addendum to the original consent form that captures the participant's or the participant's legally acceptable representative's dated signature.

Specifics about the study and the study population are to be included in the study informed consent form.

Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and Sponsor requirements.

8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research

The investigator or medically qualified designee will explain the FBR consent to the participant, or the participant's legally acceptable representative, answer all of his/her questions, and obtain documented informed consent before performing any procedure related to FBR. A copy of the informed consent will be given to the participant before performing any procedure related to FBR.

8.1.2 Inclusion/Exclusion Criteria

All inclusion and exclusion criteria will be reviewed by the investigator, who is a qualified physician, to ensure that the participant qualifies for the study.

8.1.3 Participant Identification Card

All participants will be given a participant identification card identifying them as participants in a research study. The card will contain study-site contact information (including direct telephone numbers) to be used in the event of an emergency. The investigator or qualified designee will provide the participant with a participant identification card immediately after the participant provides documented informed consent. At the time of intervention randomization, site personnel will add the treatment/randomization number to the participant identification card.

The participant ID card also contains contact information for the emergency unblinding call center so that a health care provider can obtain information about study intervention in emergency situations where the investigator is not available.

8.1.4 Medical History

A medical history will be obtained by the investigator or qualified designee. The participant's relevant medical history for the 5 years before Visit 1 will be obtained to ensure that the participant satisfies the inclusion and exclusion criteria of the study. History of tobacco use will be collected for all participants.

8.1.5 Prior and Concomitant Medications Review

8.1.5.1 Prior Medications

The investigator or qualified designee will review and record prior vaccinations and medication taken by the participant within 30 days before study vaccination at Visit 1.

The following must be documented before vaccination at Visit 1 and recorded on the appropriate eCRF:

- Any analgesic or antipyretic medication taken on the day of vaccination before vaccination.

8.1.5.2 Concomitant Medications

The investigator or qualified designee will record vaccinations and medications, if any, taken by the participant during the study.

Any analgesic or antipyretic medication taken must be recorded on the eVRC and appropriate eCRF.

The participant will use their eVRC (Section 8.1.9) to record new and/or concomitant medications taken and nonstudy vaccines received from the day of vaccination through 30 days postvaccination.

8.1.6 Assignment of Screening Number

All consented participants will be given a unique screening number that will be used to identify the participant for all procedures that occur before randomization. Each participant will be assigned only 1 screening number. Screening numbers must not be reused for different participants.

8.1.7 Assignment of Treatment/Randomization Number

All eligible participants will be randomly allocated and will receive a treatment/randomization number. The treatment/randomization number identifies the participant for all procedures occurring after treatment randomization. Once a treatment/randomization number is assigned to a participant, it can never be reassigned to another participant.

A single participant cannot be assigned more than 1 treatment/randomization number.

8.1.8 Study Intervention Administration

Unblinded study personnel will prepare and administer all study vaccines (Section 6.3.3). The unblinded study personnel who administer study vaccines should not have contact with participants for any other study related procedures/assessments.

Blinded site personnel will not be present in the examination room when study vaccines are administered.

Study vaccines should be prepared and administered by appropriately qualified members of the study personnel (eg, physician, nurse, physician's assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by local/state, country, and institutional

guidance. Procedures for handling, preparing, and administering the unblinded vaccines are provided in the Investigator Trial File Binder.

Study vaccine will be administered as a single IM injection, preferably in the deltoid region of the participant's arm, according to the schedule specified in Section 1.3. Adequate treatment provision, including epinephrine and equipment for maintaining an airway, should be available for immediate use should an anaphylactic or anaphylactoid reaction occur [Centers for Disease Control and Prevention 2015].

8.1.8.1 Timing of Dose Administration

Study vaccines will be administered as indicated in Section 1.3. Vaccinations may be administered at any time of day and without regard to timing of meals.

All participants will be observed for at least 30 minutes after vaccination for any immediate reactions (Section 8.3.4). This observation must be performed by blinded site personnel (Section 6.3.3).

Participants must not have a fever reported within 72 hours before vaccination (Section 1.3 and Section 8.3.3).

Administration of pregnancy tests (if applicable) must be performed before vaccine administration.

The collection of blood samples should be performed before vaccine administration.

8.1.9 Electronic Vaccination Report Card

The eVRC is structured as recommended in the final FDA Patient Reported Outcome Guidance [U.S. Food and Drug Administration 2009].

The participant will use the eVRC to record body temperature (Section 8.3.3), solicited injection-site AEs, and solicited systemic AEs (Section 8.4.8.1). Unsolicited AEs (Section 8.4.8.2), concomitant medications (including use of any analgesic or antipyretic medication), and nonstudy vaccinations (Section 8.1.5.2) will also be reported. Participants will be provided an electronic device or have their own electronic device configured, if compatible, to complete the eVRC.

The investigator or delegate will review the data captured on the eVRC with the participant as indicated in Section 1.3. Any differences between data reported by the participant on the eVRC and data entered into the clinical database must be clearly explained in the participant's source documents.

8.1.10 Discontinuation and Withdrawal

Participants who receive a single-dose intervention cannot discontinue study intervention (see Section 7.1).

Participants who withdraw from the study should be encouraged to complete all applicable activities scheduled for the final study visit at the time of withdrawal. Any AEs that are present at the time of withdrawal should be followed in accordance with the safety requirements outlined in Section 8.4.

8.1.10.1 Withdrawal From Future Biomedical Research

Participants may withdraw their consent for FBR. Participants may withdraw consent at any time by contacting the study investigator. If medical records for the study are still available, the investigator will contact the Sponsor using the designated mailbox (clinical.specimen.management@MSD.com). Subsequently, the participant's consent for FBR will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the responsibility of the investigator to inform the participant of completion of withdrawal. Any analyses in progress at the time of request for withdrawal or already performed before the request being received by the Sponsor will continue to be used as part of the overall research study data and results. No new analyses would be generated after the request is received.

If the medical records for the study are no longer available (eg, if the investigator is no longer required by regulatory authorities to retain the study records) or the specimens have been completely anonymized, there will no longer be a link between the participant's personal information and their specimens. In this situation, the request for specimen withdrawal cannot be processed.

8.1.11 Participant Blinding/Unblinding

STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY EFFORT SHOULD BE MADE NOT TO UNBLIND.

For emergency situations where the investigator or medically qualified designee (consistent with local requirements) needs to identify the intervention used by a participant and/or the dosage administered, he/she will contact the emergency unblinding call center by telephone and make a request for emergency unblinding. As requested by the investigator or medically qualified designee, the emergency unblinding call center will provide the information to him/her promptly and report unblinding to the Sponsor. Before contacting the emergency unblinding call center to request unblinding of a participant's intervention assignment, the investigator who is a qualified physician should make reasonable attempts to enter the intensity grade of the AEs observed, the relation to study intervention, the reason thereof, etc, in the medical record. If it is not possible to record this assessment in the medical record before the unblinding, the unblinding should not be delayed.

If unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and person performing the unblinding) must be documented promptly, and the Sponsor Clinical Director notified as soon as possible.

Once an emergency unblinding has taken place, the investigator, site personnel, and Sponsor personnel may be unblinded so that the appropriate follow-up medical care can be provided to the participant.

Participants whose treatment assignment has been unblinded by the investigator or medically qualified designee and/or nonstudy treating physician must be discontinued from study intervention, but should continue to be monitored in the study.

Additionally, the investigator or medically qualified designee must go into the IRT system and perform the unblind in the IRT system to update drug disposition. If the emergency unblinding call center is not available for a given site in this study, the IRT system should be used for emergency unblinding if this is required for participant safety.

8.1.12 Calibration of Equipment

The investigator or qualified designee has the responsibility to ensure that any device or instrument used for a clinical evaluation/test during a clinical study that provides information about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. Documentation of equipment calibration must be retained as source documentation at the study site.

8.2 Immunogenicity Assessments

Sera from participants will be used to measure vaccine-induced OPA and IgG responses. These endpoints will be tested for all immunogenicity blood draws specified in Section 1.3. Blood collection, storage, and shipment instructions for serum samples will be provided in the operations/laboratory manual.

The MOPA will be used for measuring OPA responses. Opsonization of pneumococci for phagocytosis is an important mechanism by which antibodies to polysaccharides protect against disease in vivo. The OPA assay is a useful tool for assessing the protective function of serotype-specific antibodies and, therefore, the immunogenicity of pneumococcal vaccine formulations.

Serotype-specific IgG will be measured using the Pn ECL assay to assess the concentration of binding antibodies to capsular polysaccharide of *S pneumoniae*.

After completion of immunogenicity testing to evaluate the study objectives and hypotheses, serum samples will be stored to conduct any additional study-related testing as requested by regulatory agencies or the Sponsor. For participants who provide optional consent for FBR, leftover sera from the study may be used for other purposes, such as the development and/or validation of pneumococcal assays after completion of all study-related immunogenicity testing.

8.2.1 Multiplex Opsonophagocytic Assay

The MOPA is an antibody-mediated killing assay that measures the ability of human serum to kill *S pneumoniae* serotypes with the help of complement and phagocytic effector cells [Burton, Robert L. and Nahm, Moon H. 2006]. The ability of the assay to simultaneously test 4 serotypes at a time reduces the amount of serum needed for testing. The assay readout is the opsonization index, which is the reciprocal of the highest dilution that gives $\geq 50\%$ bacterial killing, as determined by comparison to assay background controls. The Sponsor has developed and optimized the MOPA in a high-throughput microcolony platform, which not only covers all 21 serotypes in V116, but also includes serotypes 6C and 15B so that antibodies induced by vaccine serotypes 6A and 15C but cross-reactive to serotypes 6C and 15B, respectively, can be measured. The assay has been validated for various performance parameters of the assay including precision, ruggedness, relative accuracy/dilutional linearity, and the limit of detection of the assay.

8.2.2 Pneumococcal Electrochemiluminescence Assay

The Sponsor has developed, optimized, and validated a multiplex, ECL-based detection method for the quantitation of IgG serotype-specific antibodies. This multiplexed ECL assay not only detects all 21 serotypes contained in V116 but also detects serotypes 6C and 15B so that antibodies induced by vaccine serotypes 6A and 15C but cross-reactive to serotypes 6C and 15B, respectively, can be measured. The ECL assay is based on the Meso-Scale Discovery technology, which employs disposable multispot microtiter plates. Briefly, PnPs are bound to the surface of 96-well 10 plex carbon microplates, and serum containing purported anti-PnPs antibodies is added. The anti-PnPs antibodies bind to the coated plates and form an antibody antigen complex. The bound antibody-antigen complex can be detected using a ruthenium labeled anti-human IgG. Plates are read by measure of the chemiluminescent signal emitted from the ruthenium tag upon electrochemical stimulation initiated at the electrode surfaces of the microplates. To improve the specificity to the pneumococcal serotypes in the vaccine, C polysaccharide, CCI are used for pre-adsorption of samples, standard, and controls. Assay validation studies showed excellent performance operating characteristics for precision (intra and inter-assay), dilutability, ruggedness (to different plate lots and analysts), relative accuracy, and specificity.

8.3 Safety Assessments

Details regarding specific safety procedures/assessments to be performed in this study are provided.

Planned time points for all safety assessments are provided in the SoA.

8.3.1 Physical Examinations

A complete physical examination will be conducted by an investigator per institutional standard before vaccination at Visit 1.

Findings related to the physical examinations should be documented in the source documents. Investigators should pay special attention to clinical signs related to previous serious illnesses.

8.3.2 Pregnancy Testing

A pregnancy test (sensitive to at least 25 IU hCG) must be performed before vaccination at Visit 1 in POCBP as described in Section 1.3.

Urine or serum tests can be used and results must be negative before vaccination can occur. A detailed definition of POCBP is provided in Appendix 5.

- Pregnancy testing:
 - Pregnancy testing requirements for study inclusion are described in Section 5.1.
 - Additional serum or urine pregnancy tests may be performed, as determined necessary by the investigator or required by local regulation, to establish the absence of pregnancy at any time during the participant's participation in the study

8.3.3 Body Temperature Measurement

Each participant's body temperature must be taken by study-site staff before vaccination as described in Section 1.3. The prevaccination temperature should be documented in the participant's source documents. Participants who have febrile illness (defined as oral or tympanic temperature $\geq 38.0^{\circ}\text{C}$; axillary or temporal temperature $\geq 37.4^{\circ}\text{C}$) <72 hours before vaccination must be rescheduled.

Participants will also record oral body temperature measurements using the eVRC (Section 8.1.9) from Day 1 to Day 5 postvaccination.

8.3.4 Postvaccination Observation Period

All participants will be observed for at least 30 minutes after vaccination for any immediate reactions. If any immediate AEs are observed during this period, the time at which the event occurred within this timeframe, as well as the event itself, any concomitant medications that were administered, and resolution of the event must be recorded on the appropriate eCRF.

8.3.5 Clinical Safety Laboratory Assessments

Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for the timing and frequency.

- The investigator or medically qualified designee (consistent with local requirements) must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the CRF. The laboratory reports must be filed with the source documents. Clinically significant abnormal

laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

- All protocol-required laboratory assessments, as defined in Appendix 2, must be conducted in accordance with the laboratory manual and the SoA.
- If laboratory values from nonprotocol-specified laboratory assessments performed at the institution's local laboratory require a change in study participant management or are considered clinically significant by the investigator (eg, SAE or AE or dose modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
- For any laboratory tests with values considered clinically significantly abnormal during participation in the study or within 30 to 44 days after the last dose of study intervention, every attempt should be made to perform repeat assessments until the values return to normal or baseline or if a new baseline is established as determined by the investigator.

8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety Events

The definitions of an AE or SAE, as well as the method of recording, evaluating, and assessing causality of AE and SAE and the procedures for completing and transmitting AE, SAE, and other reportable safety event reports can be found in Appendix 3.

Adverse events, SAEs, and other reportable safety events will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).

The investigator and any designees are responsible for detecting, documenting, and reporting events that meet the definition of an AE or SAE as well as other reportable safety events. Investigators need to document if an SAE was associated with a medication error, misuse, or abuse. Investigators remain responsible for following up AEs, SAEs, and other reportable safety events for outcome according to Section 8.4.3.

The investigator, who is a qualified physician, will assess events that meet the definition of an AE or SAE as well as other reportable safety events with respect to seriousness, intensity/toxicity and causality.

8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safety Event Information

All AEs, SAEs, and other reportable safety events that occur after the participant provides documented informed consent, but before randomization, must be reported by the investigator if they cause the participant to be excluded from the study, or are the result of a protocol-specified intervention, including, but not limited to washout or discontinuation of usual therapy, diet, placebo, or a procedure.

All nonserious AEs and other reportable safety events must be reported by the investigator from the day of randomization through 30 days postvaccination.

All SAEs must be reported by the investigator throughout the duration of the individual's participation in the study, regardless of whether related to the study intervention.

Investigators are not obligated to actively seek AEs or SAEs or other reportable safety events in former study participants. However, if the investigator learns of any SAE, including a death, at any time after a participant has been discharged from the study, and the investigator considers the event to be reasonably related to the study intervention or study participation, the investigator must promptly notify the Sponsor.

All initial and follow-up AEs, SAEs, and other reportable safety events will be recorded and reported to the Sponsor or designee within the time frames as indicated in [Table 3](#).

Exception: A positive pregnancy test at the time of initial screening is not a reportable event unless the participant has received study intervention.

Table 3 Reporting Time Periods and Time Frames for Adverse Events and Other Reportable Safety Events

Type of Event	<u>Reporting Time Period:</u> Consent to Randomization/ Allocation	<u>Reporting Time Period:</u> Randomization/ Allocation through Protocol-specified Follow-up Period	<u>Reporting Time Period:</u> After the Protocol-specified Follow-up Period	Time Frame to Report Event and Follow-up Information to Sponsor:
NSAE	Report if: - due to protocol-specified intervention - causes exclusion - participant is receiving placebo run-in or other run-in treatment	Report all	Not required	Per data entry guidelines
SAE	Report if: - due to protocol-specified intervention - causes exclusion - participant is receiving placebo run-in or other run-in treatment	Report all	Report if: - drug/vaccine related. - any death until participant completion of study (Follow ongoing to outcome)	Within 24 hours of learning of event
Pregnancy/ Lactation Exposure	Report if: - participant has been exposed to any protocol-specified intervention (eg, procedure, washout or run-in treatment including placebo run-in) Exception: A positive pregnancy test at the time of initial screening is not a reportable event.	Report all	Previously reported – Follow to completion/ termination; report outcome	Within 24 hours of learning of event

Type of Event	<u>Reporting Time Period:</u> Consent to Randomization/ Allocation	<u>Reporting Time Period:</u> Randomization/ Allocation through Protocol-specified Follow-up Period	<u>Reporting Time Period:</u> After the Protocol-specified Follow-up Period	Time Frame to Report Event and Follow-up Information to Sponsor:
ECI (require regulatory reporting)	Report if: - due to intervention - causes exclusion	Report - Potential DILI - Require regulatory reporting	Not required	Within 24 hours of learning of event
ECI (do not require regulatory reporting)	Report if: - due to intervention - causes exclusion	Report - non-DILI ECIs and those not requiring regulatory reporting	Not required	Within 5 calendar days of learning of event
Cancer	Report if: - due to intervention - causes exclusion	Report all	Not required	Within 5 calendar days of learning of event (unless serious)
Overdose	Report if: - receiving placebo run-in or other run-in medication	Report all	Not required	Within 5 calendar days of learning of event

DILI=drug-induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse event.

8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events

Care will be taken not to introduce bias when detecting AEs and/or SAEs and other reportable safety events. Open-ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrence.

8.4.3 Follow-up of AE, SAE, and Other Reportable Safety Event Information

After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. All AEs, SAEs, and other reportable safety events, including pregnancy and exposure during breastfeeding, ECIs, cancer, and overdose will be followed until resolution, stabilization, until the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3). In addition, the investigator will make every attempt to follow all nonserious AEs that occur in randomized participants for outcome. Further information on follow-up procedures is given in Appendix 3.

8.4.4 Regulatory Reporting Requirements for SAE

Prompt notification (within 24 hours) by the investigator to the Sponsor of SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.

The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The

Sponsor will comply with country-specific regulatory requirements and global laws and regulations relating to safety reporting to regulatory authorities, IRB/IECs, and investigators.

Investigator safety reports must be prepared for SUSARs according to local regulatory requirements and Sponsor policy and forwarded to investigators as necessary.

An investigator who receives an investigator safety report describing an SAE or other specific safety information (eg, summary or listing of SAE) from the Sponsor will file it along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.

8.4.5 Pregnancy and Exposure During Breastfeeding

Although pregnancy and infant exposure during breastfeeding are not considered AEs, any pregnancy or infant exposure during breastfeeding (spontaneously reported to the investigator or their designee) that occurs in a participant during the study are reportable to the Sponsor.

All reported pregnancies must be followed to the completion/termination of the pregnancy.

Any pregnancy complication will be reported as an AE or SAE.

The medical reason (example: maternal health or fetal disease) for an elective termination of a pregnancy will be reported as an AE or SAE. Prenatal testing showing that the fetus will be born with severe abnormalities/congenital anomalies that leads to an elective termination of a pregnancy will be reported as an SAE for the fetus.

Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported.

8.4.6 Disease-related Events and/or Disease-related Outcomes Not Qualifying as AEs or SAEs

Not applicable for this study.

8.4.7 Events of Clinical Interest

There are no ECIs for this study.

8.4.8 Adverse Events on the VRC

Participants will use an eVRC to report solicited and unsolicited AEs.

The definitions of solicited and unsolicited AEs can be found in Appendix 3.

8.4.8.1 Solicited Adverse Event

Solicited AEs for this study are summarized in [Table 4](#).

Table 4 Solicited Adverse Events

Type of Solicited Adverse Event	Predefined Solicited Adverse Events	Solicited Time Period
Injection site	<ul style="list-style-type: none">• Injection-site pain or tenderness (injection-site pain)• Injection-site redness (injection-site erythema)• Injection-site swelling (injection-site swelling)	Day 1 through Day 5 postvaccination
Systemic	<ul style="list-style-type: none">• Headache (headache)• Muscle aches all over body (myalgia)• Tiredness (fatigue)	Day 1 through Day 5 postvaccination

8.4.8.2 Unsolicited Adverse Events

Unsolicited AEs for this study are events that are 1) not predefined in [Table 4](#), or 2) predefined in [Table 4](#) but reported at any time outside of the solicited time period.

8.5 Treatment of Overdose

In this study, an overdose is any dose higher than 1 dose of study vaccine in any 24-hour period.

No specific information is available on the treatment of overdose.

8.6 Pharmacokinetics

PK parameters will not be evaluated in this study.

8.7 Pharmacodynamics

Pharmacodynamic parameters will not be evaluated in this study.

8.8 Biomarkers

Biomarkers are not evaluated in this study.

8.9 Future Biomedical Research Sample Collection

If the participant provides documented informed consent for FBR, the following specimens will be obtained as part of FBR:

- DNA for future research

8.10 Medical Resource Utilization and Health Economics

Medical Resource Utilization and Health Economics are not evaluated in this study.

8.11 Visit Requirements

Visit requirements are outlined in Section 1.3. Specific procedure-related details are provided in Section 8.

8.11.1 Screening

Screening procedures will be conducted at Visit 1 as outlined in Section 1.3. Potential participants will be evaluated to determine that they fulfill the entry requirements as set forth in Section 5.

If Visit 1 is rescheduled (see Section 5.2), a pregnancy test (if applicable), a body temperature measurement, and a review of inclusion/exclusion criteria, prior medications/vaccinations, and medical history must be repeated before vaccination.

8.11.2 Treatment Period/Vaccination Visit

Requirements during the treatment period are outlined in Section 1.3.

9 STATISTICAL ANALYSIS PLAN

This section outlines the statistical analysis strategy and procedures for the study. If, after the study has begun, but prior to final database lock, changes made to primary and/or key secondary hypotheses, or the statistical methods related to those hypotheses, then the protocol will be amended (consistent with ICH Guideline E9). Changes to exploratory or other non-confirmatory analyses made after the protocol has been finalized, but prior to final database lock, will be documented in a supplemental SAP (sSAP) and referenced in the Clinical Study Report (CSR) for the study. Post hoc exploratory analyses will be clearly identified in the CSR.

9.1 Statistical Analysis Plan Summary

Key elements of the statistical analysis plan are summarized below; the comprehensive plan is provided in Sections 9.2 through 9.12.

Study Design Overview	A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Japanese Adults 65 Years of Age or Older
Treatment Assignment	Approximately 440 participants will be randomly assigned in a 1:1 ratio to receive either V116 or PPSV23. Randomization will be stratified by age at time of randomization (65 to 74 years, 75 to 84 years and ≥85 years)
Analysis Populations	Immunogenicity: PP population Safety: APaT population

Primary Endpoint(s)	Immunogenicity: <ul style="list-style-type: none"> Serotype-specific OPA GMTs at 30 days postvaccination for the 12 common serotypes, cross-reactive serotype 15B and unique serotype 15C contained in V116 Proportion of participants who achieve a ≥ 4-fold rise from baseline to 30 days postvaccination for OPA responses for the 8 unique serotypes in V116 (excluding 15C) Safety: <ul style="list-style-type: none"> Proportion of participants with solicited injection-site AEs (redness/erythema, swelling, and tenderness/pain) from Day 1 through Day 5 postvaccination Proportion of participants with solicited systemic AEs (muscle aches all over body/myalgia, headache, and tiredness/fatigue) from Day 1 through Day 5 postvaccination Proportion of participants with vaccine-related SAEs from Day 1 through the duration of participation in the study
Statistical Methods for Key Immunogenicity Analyses	<p>Immunogenicity analyses will be conducted for each of the 12 common serotypes, the 9 unique serotypes and cross-reactive serotype 15B for the primary immunogenicity objectives. For the primary immunogenicity hypotheses:</p> <p>H1: V116 will be considered noninferior to PPSV23 if the lower bound of the 2-sided 95% CI of the OPA GMT ratio (V116/PPSV23) for each of the 12 common serotypes is >0.5.</p> <p>H2: V116 will be considered noninferior to PPSV23 if the lower bound of the 2-sided 95% CI of the OPA GMT ratio (V116/PPSV23) is >0.5 for the cross-reactive serotype 15B.</p> <p>H3: V116 will be considered superior to PPSV23 if the lower bound of the 2-sided 95% CI of the OPA GMT ratio (V116/PPSV23) is >1.0 for the unique serotype 15C.</p> <p>For the hypotheses H1, H2 and H3, estimation of the serotype-specific OPA GMT ratios, 95% CIs, and p-values will be provided using the cLDA model [Liang, K-Y and Zeger, S. L. 2000].</p> <p>H4: V116 will be considered superior to PPSV23 if the lower bound of the 2-sided 95% CI of the difference (V116 – PPSV23) between proportions of participants with a ≥ 4-fold rise from baseline to 30 days postvaccination is >0 for each of the 8 unique serotypes in V116 (excluding 15C). The between-group difference (V116 – PPSV23), its 95% CI, and p-value will be provided using the stratified M&N method [Miettinen, O. and Nurminen, M. 1985].</p>
Statistical Methods for Key Safety Analyses	<p>For the overall safety evaluation, safety parameters will be summarized via descriptive statistics. For selected safety parameters, between-group 95% CIs will be provided for the percentage of participants using the unstratified M&N method [Miettinen, O. and Nurminen, M. 1985].</p>
Interim Analyses	<p>No interim analysis is planned.</p>
Multiplicity	<p>The study will have met its primary immunogenicity objectives if noninferiority is demonstrated with respect to the OPA GMTs for the 12 common serotypes (H1), and the cross-reactive serotype 15B (H2) and superiority of the unique serotype 15C (H3) as well as superiority with respect to the proportions of participants with ≥ 4-fold rises from baseline in OPA responses for the 8 unique serotypes (excluding 15C) (H4). All hypotheses will be tested individually for each serotype at one-sided $\alpha=0.025$.</p>

Sample Size and Power	A total of approximately 440 participants will be randomized, and approximately 90% of participants are expected to be included in the PP population. Approximately 198 participants will be included in each of vaccination groups. The overall power to demonstrate all the primary hypotheses will be ~95% at an overall one-sided $\alpha=0.025$.
------------------------------	--

9.2 Responsibility for Analyses/In-house Blinding

The statistical analysis of the data obtained from this study will be the responsibility of the Clinical Biostatistics department of the Sponsor.

This study will be conducted as a double-blind study under in-house blinding procedures. The official, final database will not be unblinded until medical/scientific review has been performed, protocol deviations have been identified, and data have been declared final and complete.

The Clinical Biostatistics department will generate the randomized allocation schedule(s) for study intervention assignment. Randomization will be implemented in an IRT system.

9.3 Hypotheses/Estimation

Objectives and hypotheses of the study are stated in Section 3.

9.4 Analysis Endpoints

9.4.1 Immunogenicity Endpoints

The primary immunogenicity endpoints for hypotheses testing include:

- Serotype-specific OPA GMTs at 30 days postvaccination for the 12 common serotypes, the unique serotype 15C contained in V116 and cross-reactive serotype 15B.
- Proportion of participants who achieve a ≥ 4 -fold rise from baseline to 30 days postvaccination for OPA responses for the 8 serotypes unique in V116 (excluding serotype 15C).

The secondary immunogenicity endpoints for immune responses include:

- Serotype-specific OPA GMTs at 30 days postvaccination for the 8 serotypes unique in V116 (excluding serotype 15C) and cross-reactive serotype 6C.
- Serotype-specific IgG GMCs at 30 days postvaccination for the 12 common serotypes and the 9 unique serotypes in V116.
- Proportion of participants who achieve a ≥ 4 -fold rise from baseline to 30 days postvaccination for OPA responses for the 12 common serotypes, the unique serotype 15C and the 2 cross-reactive serotypes (15B and 6C).

- Proportion of participants who achieve a ≥ 4 -fold rise from baseline to 30 days postvaccination for IgG responses for the 12 common serotypes and the 9 unique serotypes.
- Serotype-specific GMFRs from baseline to 30 days postvaccination for both OPA and IgG responses for the 12 common serotypes and the 9 unique serotypes.

The exploratory immunogenicity endpoints include:

- Serotype-specific IgG GMCs at 30 days postvaccination for the 2 cross-reactive serotypes (15B and 6C).
- Proportion of participants who achieve a ≥ 4 -fold rise from baseline to 30 days postvaccination for IgG responses for the 2 cross-reactive serotypes (15B and 6C).
- Serotype-specific GMFRs from baseline to 30 days postvaccination for both OPA and IgG responses for the 2 cross-reactive serotypes (15B and 6C).

9.4.2 Safety Endpoints

The safety endpoints for overall safety assessment that address the primary objective include:

- Proportion of participants with solicited injection-site AEs (redness/erythema, swelling, and tenderness/pain) from Day 1 through Day 5 postvaccination.
- Proportion of participants with solicited systemic AEs (muscle aches all over body/myalgia, headache, and tiredness/fatigue) from Day 1 through Day 5 postvaccination.
- Proportion of participants with vaccine-related SAEs from Day 1 through the duration of participation in the study.

Additional safety endpoints for overall safety assessment include:

- Proportion of participants with the broad AE categories consisting of any AE, any unsolicited AE, and any vaccine-related AE from Day 1 through Day 30 postvaccination.
- Proportion of participants with the broad AE categories consisting of any SAE, any vaccine-related SAE, and death from Day 1 through the duration of participation in the study. As this is a single-dose study, the broad AE category of discontinuation of study intervention due to an AE is not applicable.
- Proportion of participants with maximum temperature measurements meeting the Brighton Collaboration cut points from Day 1 through Day 5 postvaccination.

9.5 Analysis Populations

9.5.1 Immunogenicity Analysis Populations

The PP population will serve as the primary population for the analysis of immunogenicity data in this study. The PP population consists of all randomized participants without deviations from the protocol that may substantially affect the results of the immunogenicity endpoint(s). Potential deviations that may result in the exclusion of a participant from the PP population for all immunogenicity analyses include:

- Failure to receive any study vaccine at Visit 1 (Day 1)
- Failure to receive correct clinical material as per randomization schedule at Visit 1 (Day 1)
- Receipt of prohibited medication or prohibited vaccine before study vaccination

Additional potential deviations that may result in the exclusion of a participant's measurement from a specific time point assessment in the PP population for immunogenicity analyses include:

- Receipt of prohibited medication or prohibited vaccine before a blood sample collection
- Collection of blood sample outside the prespecified window

The final determination on protocol deviations, and thereby the composition of the PP population, will be made prior to the final unblinding of the database and will be documented in a separate memo.

A supportive analysis using the FAS population will also be performed for the primary immunogenicity endpoints. The FAS population consists of all randomized participants who received study vaccination and have at least 1 serology result. Participants will be included in the vaccination group to which they are randomized for the analysis of immunogenicity data using the FAS population.

9.5.2 Safety Analysis Populations

Safety analyses will be conducted in the APaT population, which consists of all randomized participants who receive study intervention. Participants will be included in the group corresponding to the study intervention they actually receive for the analysis of safety data using the APaT population. This will be the group to which they are randomized except for participants who receive incorrect study intervention; such participants will be included in the intervention group corresponding to the study intervention actually received.

At least 1 temperature measurement obtained subsequent to study intervention is required for inclusion in the analyses of temperature.

9.6 Statistical Methods

9.6.1 Statistical Methods for Immunogenicity Analyses

This section describes the statistical methods that address the primary and secondary immunogenicity objectives. Methods related to exploratory objectives will be described in the sSAP.

Immunogenicity analyses will be conducted for each serotype separately.

Primary Endpoints

For the 12 common serotypes and cross-reactive serotype of 15B, the primary noninferiority hypotheses (H1 and H2) regarding OPA GMT levels between recipients of V116 and PPSV23 are:

$H_0: \text{GMT}_1/\text{GMT}_2 \leq 0.5$ versus

$H_1: \text{GMT}_1/\text{GMT}_2 > 0.5$

where GMT_1 is the serotype-specific OPA GMT for the V116 group and GMT_2 is the serotype-specific OPA GMT for the PPSV23 group. A ratio of 0.5 corresponds to an OPA GMT that is 2-fold lower in the V116 group compared with the PPSV23 group. Rejecting the null hypotheses (H_0) at one-sided $\alpha=0.025$ corresponds to the lower bound of the 2-sided 95% CI for the GMT ratio (V116/PPSV23) being >0.5 and will lead to the conclusion that the OPA responses to V116 are noninferior to that of PPSV23.

For the serotype 15C that is unique to V116, the primary superiority hypothesis (H3) regarding OPA GMT levels between recipients of V116 and PPSV23 is:

$H_0: \text{GMT}_1/\text{GMT}_2 \leq 1.0$ versus

$H_1: \text{GMT}_1/\text{GMT}_2 > 1.0$

where GMT_1 is the serotype-specific OPA GMT for the V116 group, GMT_2 is the serotype-specific OPA GMT for the PPSV23 group. Rejecting the null hypothesis (H_0) at one-sided $\alpha=0.025$ corresponds to the lower bound of the 2-sided 95% CI for the GMT ratio (V116/PPSV23) being >1.0 for the serotype 15C and would lead to the conclusion that the OPA responses to V116 for this serotype is superior to that of PPSV23.

To address the first primary immunogenicity objective, and corresponding hypotheses H1, H2 and H3, the serotype-specific OPA GMTs at 30 days postvaccination will be compared between vaccination groups. The GMT ratio estimation, 95% CI, and the hypotheses testing (ie, one-sided p-value) will be provided based on a cLDA model proposed by Liang and Zeger [Liang, K-Y and Zeger, S. L. 2000] using data from both vaccination groups. In this model, the response vector consists of the log-transformed antibody titers at baseline and 30 days postvaccination. The model will include terms for time, vaccination group, the interaction of time-by-vaccination group, age stratum (ie, 65 to 74 years, 75 to 84 years and

≥85 years of age) at baseline, and the interaction of time-by-age stratum. This model will allow for different baseline means for each age stratum, but restrict the baseline mean within each age stratum to be the same for all vaccination groups. For the analysis purpose of first and second primary objectives, the age stratum of 75 to 84 years and ≥85 years may be combined to ensure sufficient numbers of participants although these groups are separate stratum for randomization. An unstructured covariance matrix will be used to model the correlation among repeated measurements. The term for time will be treated as a categorical variable. The Kenward-Roger adjustment will be used with REML to make proper statistical inference. This model allows the inclusion of participants who are missing either the baseline or postbaseline measurements, thereby increasing efficiency.

The second primary objective (H4: to compare the proportions of participants with a ≥4-fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination with V116 versus PPSV23) will be assessed via the following superiority hypotheses for the 8 serotypes that are unique to V116 (excluding serotype 15C):

$H_0: p_1 - p_2 \leq 0$ versus

$H_1: p_1 - p_2 > 0$

where p_1 and p_2 are the proportions of participants with a ≥4-fold rise in serotype-specific OPA responses from baseline to 30 days postvaccination for the V116 group and PPSV23 group, respectively. Rejecting the null hypotheses (H_0) at one-sided $\alpha=0.025$ corresponds to that the lower bound of the 2-sided 95% CI for the difference (V116 – PPSV23) being >0 and will lead to the conclusion that the proportion of participants with a ≥4-fold rise in OPA responses in the V116 group for the 8 unique serotype (excluding serotype 15C) are superior to those in the PPSV23 group.

To address the second primary immunogenicity objective, the proportion of participants with a ≥4-fold rise in serotype-specific OPA responses will be compared between vaccination groups. Comparisons will be made through the estimation of the difference in the proportion of participants with a ≥4-fold rise in serotype-specific OPA responses for the unique serotypes in V116. The participants who are missing either baseline or 30 days postvaccination OPA responses will not be included in the fold-rise calculation. Estimation of the difference in proportion with its 95% CI and the hypotheses test (ie, one-sided p-value) will be provided using the stratified M&N method with stratification by the participant's age at the time of randomization (65 to 74 years, 75 to 84 years and ≥85 years), an unconditional and, asymptotic method [Miettinen, O. and Nurminen, M. 1985]. The weights of the stratified M&N will be based on the sample size of each age stratum.

Secondary Endpoints

A similar statistical model used for the first primary objective will be used to address the secondary objective that compares the serotype-specific IgG GMCs and OPA GMTs at 30 days postvaccination in V116 with those in PPSV23.

A similar statistical method used for the second primary objective will be used to address the secondary objective that compares the proportion of participants with a ≥ 4 -fold rise in serotype-specific OPA responses at 30 days postvaccination in V116 with those in PPSV23.

Descriptive statistics including point estimates and within-group 95% CIs will be provided for all other immunogenicity endpoints. For the continuous endpoints, the point estimates and the within group CIs will be obtained by exponentiating the point estimates and the upper and lower bounds of the CIs for the mean on the natural log scale based on the t-distribution. For the dichotomous endpoints, the within-group CIs will be provided using the exact Binomial method proposed by Clopper and Pearson [CLOPPER, C. J. and PEARSON, E. S. 1934]. For titers and concentrations that are less than the lower limit of the assay's detectable range, half of the lower limit will be used as the value of them. For GMFR, the lower limit will be used as the value.

Reverse Cumulative Distribution Curves for both OPA titers and IgG concentrations at 30 days postvaccination will be provided by serotype.

A detailed analysis strategy for immunogenicity endpoints is listed in [Table 5](#).

Table 5 Analysis Strategy for Immunogenicity Variables

Endpoint/Variable (Description, Time Point)	Primary vs. Supportive Approach ^a	Statistical Method	Analysis Population	Missing Data Approach
Primary Endpoints				
OPA GMTs at 30 days postvaccination for the 12 common serotypes, the cross-reactive serotype 15B and the unique serotype 15C	P	cLDA ^b (estimate, 95% CI, p-values)	PP	Model-based
	S		FAS	
Proportions of participants with a ≥4-fold rise from baseline to 30 days postvaccination for OPA responses for the 8 unique serotypes in V116 (excluding serotype 15C)	P	Stratified M&N ^c (estimate of difference, 95% CI, p-value)	PP	Missing data will not be imputed
	S		FAS	
Secondary Endpoints				
OPA GMTs at 30 days postvaccination for the 8 unique serotypes in V116 (excluding serotype 15C) and cross-reactive serotype 6C	P	cLDA ^b (estimate, 95% CI)	PP	Model-based
IgG GMCs at 30 days postvaccination for the 12 common serotypes and the 9 unique serotypes	P	cLDA ^b (estimate, 95% CI)	PP	Model-based
Proportions of participants with a ≥4-fold rise from baseline to 30 days postvaccination for OPA responses for the 12 common serotypes and the unique serotype 15C and for the 2 cross-reactive serotypes (15B and 6C)	P	Stratified M&N ^c (estimate of difference, 95% CI)	PP	Missing data will not be imputed

Endpoint/Variable (Description, Time Point)	Primary vs. Supportive Approach ^a	Statistical Method	Analysis Population	Missing Data Approach
Proportions of participants with a ≥ 4 -fold rise from baseline to 30 days postvaccination for IgG responses for the 12 common serotypes and the 9 unique serotypes	P	Descriptive Statistics (estimate, 95% CI)	PP	Missing data will not be imputed
GMFRs from baseline to 30 days postvaccination for both OPA and IgG responses for the 12 common serotypes and the 9 unique serotypes in V116	P	Descriptive Statistics (estimate, 95% CI)	PP	Missing data will not be imputed
cLDA=constrained longitudinal data analysis; FAS=full analysis set; GMC=geometric mean concentration; GMFR=geometric mean fold rise; GMT=geometric mean titer; IgG=immunoglobulin G; M&N=Miettinen and Nurminen; OPA=opsonophagocytic activity; PP=per-protocol. ^a P = Primary approach; S = Supportive approach. ^b cLDA model with terms for vaccination group, time, the interaction of time-by-vaccination, age stratum (ie, 65 to 74 years, 75 to 84 years and ≥ 85 years) at baseline, and the interaction of time-by-age stratum. ^c Stratified analysis using the M&N method [Miettinen, O. and Nurminen, M. 1985] with stratification by the participant's age at the time of randomization (65 to 74 years, 75 to 84 years and ≥ 85 years).				

9.6.2 Statistical Methods for Safety Analyses

Safety and tolerability will be assessed by clinical review of all relevant parameters, including AEs and postvaccination temperature measurements.

9.6.2.1 Overall Safety Assessment

The overall safety evaluation will include a summary by intervention group (V116 group and PPSV23 group) of the number and percentage of participants with any AEs, any unsolicited AEs, any vaccine-related AEs, any SAEs, any vaccine-related SAEs, and any AEs resulting in death after vaccination. Point estimates and 95% CIs for the between-group differences (V116 compared with PPSV23) in the percentages of participants with events will be provided for these events.

The number and percentage of participants with specific AEs will also be provided. And the point estimates and 95% CIs for difference between intervention groups in the percentages of participants with specific AEs will be provided for solicited AEs and AEs with an incidence of 4 participants in the V116 group or PPSV23 group.

The above thresholds for the numbers of events were chosen because the 95% CI for the between-group difference in percent incidence will always include zero when fewer participants per vaccination group have events and thus would add little to the interpretation of potentially meaningful differences.

The number and percentage of participants with maximum temperature measurements meeting the Brighton Collaboration cut points [Marcy, S. M., et al 2004] will be provided along with point estimates and 95% CIs of between-group differences.

CI's for between-group differences will be provided using the unstratified M&N method [Miettinen, O. and Nurminen, M. 1985]. CI's that are not adjusted for multiplicity should only be regarded as helpful descriptive measures for the review of the safety profile and not as a formal method for assessing statistical significance of between-group differences. Rainfall plots with point estimates and 95% CI's will be displayed for AEs that occur in $\geq 5\%$ of participants in the V116 group or PPSV23 group.

The analysis strategy for safety endpoints is summarized in [Table 6](#).

Table 6 Analysis Strategy for Safety Parameters

Analysis Part	Safety Endpoint	Descriptive Statistics	95% Between-group CI	Graphical Display
Overall Safety Assessment	Solicited injection-site AE (Day 1 through Day 5 postvaccination) ^a	X	X	
	Solicited systemic AE (Day 1 through Day 5 postvaccination) ^a	X	X	
	Any AE ^b	X	X	
	Any unsolicited AE ^b	X	X	
	Any vaccine-related AE ^b	X	X	
	Any SAE ^b	X	X	
	Any vaccine-related SAE ^b	X	X	
	Death ^b	X	X	
	Specific AEs by SOC and PT ^c	X	X	X
	Maximum temperatures (Day 1 through Day 5 postvaccination) ^d	X	X	

AE=adverse event; CI=Confidence Interval; PT=Preferred term; SAE=serious adverse event; SOC=System Organ Class.

^a Solicited injection-site AEs include redness/erythema, swelling, and tenderness/pain; solicited systemic AEs include muscle aches all over body/myalgia, headache, and tiredness/fatigue.

^b These endpoints are broad AE categories. For example, descriptive statistics for the safety endpoint of "Any AE" will provide the number and percentage of participants with at least 1 AE.

^c Descriptive statistics and graphical displays will be provided for specific AEs with an incidence $>0\%$ and $\geq 5\%$ of participants, respectively, in either intervention group. The 95% between-group CI will be provided for specific AEs with an incidence ≥ 4 participants in the V116 group or PPSV23 group.

^d Maximum temperature measurements are categorized by Brighton Collaboration cut points.

9.6.3 Demographic and Baseline Characteristics

The comparability of the vaccination groups for each relevant demographic and baseline characteristic will be assessed by the use of summary tables. No statistical hypothesis tests will be performed on these characteristics. The number and percentage of participants randomized and discontinued from the study and discontinuation reasons will be displayed. Demographic variables (eg, age, sex, and gender), baseline characteristics, and prior and concomitant vaccinations and medications will be summarized by vaccination group either by descriptive statistics or categorical tables.

9.7 Interim Analyses

No interim analysis is planned.

9.8 Multiplicity

The study will have met its primary immunogenicity objectives if noninferiority is demonstrated with respect to the OPA GMTs for the 12 common serotypes (H1), and the cross-reactive serotype 15B (H2) and superiority of the 1 unique serotype 15C (H3) as well as superiority with respect to the proportions of participants with ≥ 4 -fold rises from baseline in OPA responses for the 8 unique serotypes (excluding 15C) (H4). All hypotheses will be tested individually for each serotype at one-sided $\alpha=0.025$.

9.9 Sample Size and Power Calculations

9.9.1 Sample Size and Power for Immunogenicity Analyses

For the primary hypotheses, this study has approximately 95% power to demonstrate noninferiority to PPSV23 for the 12 common serotypes and 1 cross-reactive serotype 15B and superiority for the 9 unique serotypes for V116 at an overall one-sided $\alpha=0.025$.

The sample size and power calculations are based on V116-002 Subgroup (65 years of age and older).

Assumptions and power for GMTs and proportions of participants with a ≥ 4 -fold rise from baseline OPA responses for each serotype are shown in [Table 7](#) and [Table 8](#), respectively.

Table 7 Assumption of OPA GMT ratio (V116/PPSV23) and power for each of the 12 common serotypes, the cross-reactive serotype 15B, and the unique serotype 15C with 440 participants

Serotype	GMT Ratio (V116/PPSV23)	SD of Natural Log Titers	Power
Common Serotype: non-inferiority margin is 0.5			
3	1.38	1.00	>99%
7F	1.42	1.56	>99%
19A	2.04	1.37	>99%
22F	2.72	1.75	>99%
33F	1.11	1.23	>99%
8	1.90	1.04	>99%
9N	2.05	1.28	>99%
10A	2.64	1.61	>99%
11A	2.20	1.25	>99%
12F	2.88	1.88	>99%
17F	2.67	1.33	>99%
20A	3.02	1.16	>99%

Serotype	GMT Ratio (V116/PPSV23)	SD of Natural Log Titers	Power
Cross reactive Serotype: non-inferiority margin is 0.5			
15B	2.23	1.58	>99%
Unique Serotype: superiority margin is 1.0			
15C	2.88	1.67	>99%
GMT=geometric mean titer; SD=standard deviation The power is based on the assumption that 90% of randomized participants are included in the analysis population.			

Table 8 Assumption of the proportion of participants with a ≥ 4 -fold rise from baseline OPA responses and power for each of the 8 unique serotypes (excluding 15C) with 440 participants

Serotype	V116	PPSV23	Difference	Power
Unique Serotypes: superiority				
6A	67.6%	50.0%	17.6%	95%
15A	58.8%	26.5%	32.3%	>99%
16F	73.5%	24.2%	49.3%	>99%
23A	82.4%	20.6%	61.8%	>99%
23B	87.9%	55.9%	32.0%	>99%
24F	71.0%	3.4%	67.6%	>99%
31	82.4%	14.7%	67.7%	>99%
35B	61.8%	5.9%	55.9%	>99%
The calculations are based on an asymptotic method proposed by Farrington and Manning (1990) [Farrington, C. P. 1990]. The power is based on the assumption that 90% of randomized participants are included in the analysis population.				

9.9.2 Sample Size and Power for Safety Analyses

The probability of observing at least 1 SAE in this study depends on the number of participants vaccinated and the underlying incidence of participants with an SAE in the study population. Calculations below assume that 100% of the randomized participants will be evaluable for safety analyses. There is an 83% chance of observing at least 1 SAE among 220 participants in V116 group if the underlying incidence of an SAE is 0.8% (1 of every 125 participants receiving the vaccine). There is a 59% chance of observing at least 1 SAE among 220 participants in the V116 group if the underlying incidence of an SAE is 0.4% (1 of every 250 participants receiving the vaccine). If no SAEs are observed among 220 participants, this study will provide 97.5% confidence that the underlying percentage of participants with an SAE is $<1.98\%$ (1 in every 51 participants) in the V116 group.

The percentage point differences between the 2 vaccination groups that could be detected with 80% probability are summarized in [Table 9](#) for a variety of hypothetical underlying incidences of an AE.

Table 9 Differences in Incidence of Adverse Event Rates Between the 2 Vaccination Groups That Can be Detected With an Approximately 80% Probability

Incidence of Adverse Event		Risk Difference (Percentage Points)
V116 (%) N=220	PPSV23 (%) N=220	
3.8	0.1	3.7
7.8	2.0	5.8
12.6	5.0	7.6
19.5	10.0	9.5
25.8	15.0	10.8
31.7	20.0	11.7
42.9	30.0	12.9
The incidences presented here are hypothetical and do not represent actual adverse experiences in either group. The incidences assume two sided 5% alpha-level with 220 participants in each group. No multiplicity adjustments were made. The calculations are based on an asymptotic method proposed by Farrington and Manning (1990) [Farrington, C. P. 1990].		

9.10 Subgroup Analyses

Subgroup analyses will be performed for selected safety endpoints as well as the primary immunogenicity endpoints. The following subgroups are planned for evaluation:

- Age category (65 to 74, 75 to 84, ≥85 years of age)
- Sex
- Chronic medical condition

Further details of subgroup analyses will be documented in the sSAP.

9.11 Compliance (Medication Adherence)

Given that participants will receive a single dose of V116 or PPSV23, compliance will not be calculated. However, the number and proportion of randomized participants receiving V116 or PPSV23 will be summarized by vaccination group.

9.12 Extent of Exposure

The extent of exposure will be summarized by the number and proportion of randomized participants administered V116 or PPSV23 in each vaccination group.

10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS

10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations

10.1.1 Code of Conduct for Clinical Trials

Merck Sharp & Dohme LLC, Rahway, NJ, USA (MSD)

Code of Conduct for Interventional Clinical Trials

I. Introduction

A. Purpose

MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted in compliance with local and/or national regulations (including all applicable data protection laws and regulations), and International Council for Harmonisation Good Clinical Practice (ICH-GCP), and also in accordance with the ethical principles that have their origin in the Declaration of Helsinki.

B. Scope

Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by MSD irrespective of the party (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or which are retrospective. Further, this Code does not apply to investigator-initiated trials, which are not under the full control of MSD.

II. Scientific Issues

A. Trial Conduct

1. Trial Design

Except for pilot or estimation trials, clinical trial protocols will be hypothesis-driven to assess safety, efficacy and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine patient preferences, etc.

The design (i.e., participant population, duration, statistical power) must be adequate to address the specific purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where applicable, third parties. All trial protocols are and will be assessed for the need and capability to enroll underrepresented groups. Participants must meet protocol entry criteria to be enrolled in the trial.

2. Site Selection

MSD's clinical trials are conducted globally in many different countries and in diverse populations, including people of varying age, race, ethnicity, gender, and accounting for other potential disease related factors. MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial initiation, sites are evaluated by MSD personnel (or individuals acting on behalf of MSD) to assess the ability to successfully conduct the trial.

Where appropriate, and in accordance with regulatory authority guidance, MSD will make concerted efforts to raise awareness of clinical trial opportunities in various communities. MSD will seek to engage

underrepresented groups and those disproportionately impacted by the disease under study. MSD will support clinical trial investigators to enroll underrepresented groups and expand access to those who will ultimately use the products under investigation.

3. Site Monitoring/Scientific Integrity

Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus source documentation according to standard operating procedures. Per MSD policies and procedures, if potential fraud, scientific/research misconduct, privacy incidents/breaches or Clinical Trial-related Significant Quality Issues are reported, such matters are investigated. When necessary, appropriate corrective and/or preventative actions are defined and regulatory authorities and/or ethics review committees are notified.

B. Publication and Authorship

Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of marketed products in which treatment is assigned, according to the pre-specified plans for data analysis. To the extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis-generating rather than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues such as multiplicity.

MSD's policy on authorship is consistent with the recommendations published by the International Committee of Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in publications.

III. Participant Protection

A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics Committee [IEC])

All protocols and protocol amendments will be submitted by MSD for regulatory authority acceptance/authorization prior to implementation of the trial or amendment, in compliance with local and/or national regulations.

The protocol, protocol amendment(s), informed consent form, investigator's brochure, and other relevant trial documents must be reviewed and approved by an IRB/IEC before being implemented at each site, in compliance with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with local and/or national regulations.

B. Safety

The guiding principle in decision-making in clinical trials is that participant welfare is of primary importance. Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial designs will take into account the local standard of care.

All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or receipt of, medical care that may otherwise be available to them.

C. Confidentiality

MSD is committed to safeguarding participant confidentiality, to the greatest extent possible, as well as all applicable data protection rights. Unless required by law, only the investigator, Sponsor (or individuals acting on

behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records that might identify the participant by name.

D. Genomic Research

Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an ethics committee.

IV. Financial Considerations

A. Payments to Investigators

Clinical trials are time- and labor-intensive. It is MSD's policy to compensate investigators (or the sponsoring institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be made to compensate for the time spent in extra recruiting efforts.

MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent on chart review and medical evaluation to identify potentially eligible participants.

B. Clinical Research Funding

Informed consent forms will disclose that the trial is sponsored by MSD, and that the investigator or sponsoring institution is being paid or provided a grant for performing the trial. However, the local ethics committee may wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.

C. Funding for Travel and Other Requests

Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be consistent with local guidelines and practices.

V. Investigator Commitment

Investigators will be expected to review MSD's Code of Conduct as an appendix to the trial protocol, and in signing the protocol, agree to support these ethical and scientific standards.

10.1.2 Financial Disclosure

Financial disclosure requirements are outlined in the US Food and Drug Administration Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54). It is the Sponsor's responsibility to determine, based on these regulations, whether a request for financial disclosure information is required. It is the investigator's/subinvestigator's responsibility to comply with any such request.

The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to allow for the submission of complete and accurate certification and disclosure statements. The investigator/subinvestigator(s) further agree to provide this information on a Certification/Disclosure Form, frequently known as a financial disclosure form, provided by the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this information to the Sponsor in the United States for these purposes. This may involve the transmission of information to countries that do not have laws protecting personal data.

10.1.3 Data Protection

The Sponsor will conduct this study in compliance with all applicable data protection regulations.

Participants will be assigned a unique identifier by the Sponsor. Any participant records or datasets that are transferred to the Sponsor will contain the identifier only; participant names or any information that would make the participant identifiable will not be transferred.

The participant must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant.

The participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.

10.1.3.1 Confidentiality of Data

By signing this protocol, the investigator affirms to the Sponsor that information furnished to the investigator by the Sponsor will be maintained in confidence, and such information will be divulged to the IRB, IEC, or similar or expert committee; affiliated institution and employees, only under an appropriate understanding of confidentiality with such board or committee, affiliated institution and employees. Data generated by this study will be considered confidential by the investigator, except to the extent that it is included in a publication as provided in the Publications section of this protocol.

10.1.3.2 Confidentiality of Participant Records

By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to verify worksheet/CRF data. By signing the consent form, the participant agrees to this process. If study documents will be photocopied during the process of verifying worksheet/CRF information, the participant will be identified by unique code only; full names/initials will be masked before transmission to the Sponsor.

By signing this protocol, the investigator agrees to treat all participant data used and disclosed in connection with this study in accordance with all applicable privacy laws, rules and regulations.

10.1.3.3 Confidentiality of IRB/IEC Information

The Sponsor is required to record the name and address of each IRB/IEC that reviews and approves this study. The Sponsor is also required to document that each IRB/IEC meets regulatory and ICH GCP requirements by requesting and maintaining records of the names and qualifications of the IRB/IEC members and to make these records available for regulatory agency review upon request by those agencies.

10.1.4 Publication Policy

The results of this study may be published or presented at scientific meetings. The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement.

If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.

Authorship will be determined by mutual agreement and in line with ICMJE authorship requirements.

10.1.5 Compliance with Study Registration and Results Posting Requirements

Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the Sponsor of the study is solely responsible for determining whether the study and its results are subject to the requirements for submission to <http://www.clinicaltrials.gov>, www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will review this protocol and submit the information necessary to fulfill these requirements. MSD entries are not limited to FDAAA or the EMA clinical trials directive mandated trials. Information posted will allow participants to identify potentially appropriate studies for their disease conditions and pursue participation by calling a central contact number for further information on appropriate study locations and study-site contact information.

By signing this protocol, the investigator acknowledges that the statutory obligations under FDAAA, the EMA clinical trials directive, or other locally mandated registries are that of the Sponsor and agrees not to submit any information about this study or its results to those registries.

10.1.6 Compliance with Law, Audit, and Debarment

By signing this protocol, the investigator agrees to conduct the study in an efficient and diligent manner and in conformance with this protocol; generally accepted standards of GCP (eg, ICH GCP: Consolidated Guideline and other generally accepted standards of GCP); and all applicable federal, state and local laws, rules and regulations relating to the conduct of the clinical study.

The Code of Conduct, a collection of goals and considerations that govern the ethical and scientific conduct of clinical investigations sponsored by MSD, is provided in this appendix under the Code of Conduct for Clinical Trials.

The investigator agrees not to seek reimbursement from participants, their insurance providers, or from government programs for procedures included as part of the study reimbursed to the investigator by the Sponsor.

The investigator will promptly inform the Sponsor of any regulatory authority inspection conducted for this study.

The investigator agrees to provide the Sponsor with relevant information from inspection observations/findings to allow the Sponsor to assist in responding to any citations resulting from regulatory authority inspection and will provide the Sponsor with a copy of the proposed response for consultation before submission to the regulatory authority.

Persons debarred from conducting or working on clinical studies by any court or regulatory authority will not be allowed to conduct or work on this Sponsor's studies. The investigator will immediately disclose in writing to the Sponsor if any person who is involved in conducting the study is debarred or if any proceeding for debarment is pending or, to the best of the investigator's knowledge, threatened.

10.1.7 Data Quality Assurance

All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator or qualified designee is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.

Detailed information regarding Data Management procedures for this protocol will be provided separately.

The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.

The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.

Study documentation will be promptly and fully disclosed to the Sponsor by the investigator upon request and also shall be made available at the study site upon request for inspection, copying, review, and audit at reasonable times by representatives of the Sponsor or any regulatory authorities. The investigator agrees to promptly take any reasonable steps that are requested by the Sponsor or any regulatory authorities as a result of an audit or inspection to cure deficiencies in the study documentation and worksheets/CRFs.

The Sponsor or designee is responsible for the data management of this study including quality checking of the data.

Study monitors will perform ongoing source data review and verification to confirm that data entered into the CRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.

Records and documents, including participants' documented informed consent, pertaining to the conduct of this study must be retained by the investigator for 15 years after study

completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor.

10.1.8 Source Documents

Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. The investigator/institution should maintain adequate and accurate source documents and study records that include all pertinent observations on each of the site's participants. Source documents and data should be attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data should be traceable, should not obscure the original entry, and should be explained if necessary (eg, via an audit trail). Source documents are filed at the investigator's site.

Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator/institution may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

10.1.9 Study and Site Closure

The Sponsor or its designee may stop the study or study-site participation in the study for medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, regulations, and GCP.

In the event the Sponsor prematurely terminates a particular study site, the Sponsor or designee will promptly notify that study site's IRB/IEC as specified by applicable regulatory requirement(s).

10.2 Appendix 2: Clinical Laboratory Tests

- The tests detailed in [Table 10](#) will be performed by the local laboratory.
- Protocol-specific requirements for inclusion or exclusion of participants are detailed in Section 5 of the protocol.
- Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations.

Table 10 Protocol-required Safety Laboratory Assessments

Laboratory Assessments	Parameters
Pregnancy Testing	<ul style="list-style-type: none">• Highly sensitive serum or urine hCG pregnancy test (as needed for POCCBP)
hCG=human chorionic gonadotropin; POCCBP=participants of childbearing potential	

The investigator (or medically qualified designee) must document their review of each laboratory safety report.

10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting

10.3.1 Definitions of Medication Error, Misuse, and Abuse

Medication Error

This is an unintended failure in the drug treatment process that leads to or has the potential to lead to harm to the patient.

Misuse

This refers to situations where the medicinal product is intentionally and inappropriately used not in accordance with the terms of the product information.

Abuse

This corresponds to the persistent or sporadic, intentional excessive use of a medicinal product for a perceived psychological or physiological reward or desired non-therapeutic effect.

10.3.2 Definition of AE

AE definition

- An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
- Note: For purposes of AE definition, study intervention (also referred to as Sponsor's product) includes any pharmaceutical product, biological product, vaccine, diagnostic agent, medical device, combination product, or protocol specified procedure whether investigational or marketed (including placebo, active comparator product, or run-in intervention), manufactured by, licensed by, provided by, or distributed by the Sponsor for human use in this study.

Events meeting the AE definition

- Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator.

- Exacerbation of a chronic or intermittent preexisting condition including either an increase in frequency and/or intensity of the condition.
- New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.
- Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication.
- For all reports of overdose (whether accidental or intentional) with an associated AE, the AE term should reflect the clinical symptoms or abnormal test result. An overdose without any associated clinical symptoms or abnormal laboratory results is reported using the terminology “accidental or intentional overdose without adverse effect.”
- Any new cancer or progression of existing cancer.

Events NOT meeting the AE definition

- Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the AE.
- Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present or detected at the start of the study that do not worsen.
- Surgical procedure(s) planned prior to informed consent to treat a preexisting condition that has not worsened.
- Refer to Section 8.4.6 for protocol-specific exceptions.

Definition of Unsolicited and Solicited AE

- An unsolicited AE is an AE that was not solicited using a VRC and that is communicated by a participant/participant’s legally authorized representative who has signed the informed consent. Unsolicited AEs include serious and nonserious AEs.
- Solicited AEs are predefined local (at the injection/administration site) and systemic events for which the participant/participant’s legally authorized representative is specifically questioned, and which are noted by the participant/participant’s legally authorized representative in their VRC.

10.3.3 Definition of SAE

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met.

An SAE is defined as any untoward medical occurrence that, at any dose:

a. Results in death

b. Is life-threatening

- The term “life-threatening” in the definition of “serious” refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.

c. Requires inpatient hospitalization or prolongation of existing hospitalization

- Hospitalization is defined as an inpatient admission, regardless of length of stay, even if the hospitalization is a precautionary measure for continued observation. (Note: Hospitalization for an elective procedure to treat a preexisting condition that has not worsened is not an SAE.) A preexisting condition is a clinical condition that is diagnosed prior to the use of an MSD product and is documented in the participant’s medical history.

d. Results in persistent or significant disability/incapacity

- The term disability means a substantial disruption of a person’s ability to conduct normal life functions.
- This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) that may interfere with or prevent everyday life functions but do not constitute a substantial disruption.

e. Is a congenital anomaly/birth defect

- In offspring of participant taking the product regardless of time to diagnosis.

f. Other important medical events

- Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the other outcomes listed in the above definition. These events should usually be considered serious.

- Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

10.3.4 Additional Events Reported

Additional events that require reporting

In addition to the above criteria, AEs meeting either of the below criteria, although not serious per ICH definition, are reportable to the Sponsor.

- Is a cancer
- Is associated with an overdose

10.3.5 Recording AE and SAE

AE and SAE recording

- When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory, and diagnostics reports) related to the event.
- The investigator will record all relevant AE/SAE information on the AE CRFs/worksheets at each examination.
- It is not acceptable for the investigator to send photocopies of the participant's medical records to the Sponsor in lieu of completion of the AE CRF page.
- There may be instances when copies of medical records for certain cases are requested by the Sponsor. In this case, all participant identifiers, with the exception of the participant number, will be blinded on the copies of the medical records before submission to the Sponsor.
- The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.

Assessment of intensity

- An event is defined as "serious" when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, not when it is rated as severe.
- The investigator will make an assessment of overall intensity grade for each AE and SAE (and other reportable event) reported during the study. An overall intensity grade will be assigned to injection-site AEs, specific systemic AEs, other systemic AEs, and vital sign (temperature) AEs as shown in the following tables. The overall intensity grading scales

used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

Injection Site AE Overall Intensity Grading Scale

Injection-Site Reaction to Study Vaccine/Placebo	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life Threatening (Grade 4)
Injection-site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo				
Pain/Tenderness	Does not interfere with activity	Repeated use of non-narcotic pain reliever >24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	ER visit or hospitalization
Erythema/Redness	Size measured as ≤5 cm	Size measured as 5.1 to 10 cm	Size measured as >10 cm	Necrosis or exfoliative dermatitis or results in ER visit or hospitalization
Swelling	Size measured as ≤5 cm	Size measured as 5.1 to 10 cm	Size measured as >10 cm	Necrosis or ER visit or hospitalization
Other	Does not interfere with activity	Repeated use of non-narcotic pain reliever >24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	ER visit or hospitalization
Any injection-site reaction that begins ≥6 days after receipt of study vaccine/placebo				
Pain/Tenderness Erythema/Redness Swelling Other	Does not interfere with activity	Repeated use of non-narcotic pain reliever >24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	ER visit or hospitalization

AE=adverse event; ER=emergency room.

The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

Specific Systemic AE Overall Intensity Grading Scale

Systemic (General)	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life Threatening (Grade 4)
Headache	No interference with activity	Repeated use of non-narcotic pain reliever >24 hours or some interference with activity	Significant; any use of narcotic pain reliever or prevents daily activity	ER visit or hospitalization
Fatigue	No interference with activity	Some interference with activity	Significant; prevents daily activity	ER visit or hospitalization
Myalgia	No interference with activity	Some interference with activity	Significant; prevents daily activity	ER visit or hospitalization

ER=emergency room

The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

Other Systemic AE Overall Intensity Grading Scale

Systemic Illness ^a	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life Threatening (Grade 4) ^b
Illness or clinical AE (as defined according to applicable regulations)	No interference with activity	Some interference with activity not requiring medical intervention	Prevents daily activity and required medical intervention	ER visit or hospitalization

AE=adverse event; ER=emergency room; eVRC=electronic Vaccine Report Card; SAE=serious adverse event

The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

^a Based upon information provided by the patient on the eVRC and verbally during the eVRC review during the primary safety follow-up period. For SAEs reported beyond the primary safety follow-up period, grading will be based upon the initial report and/or follow-up of the event.

^b AEs resulting in death will be assessed as Grade 4.

Vital Sign (Temperature) Overall Intensity Grading Scale

Vital Signs ^a	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life Threatening (Grade 4)
Fever (°C) ^b	38.0 to 38.4	38.5 to 38.9	39.0 to 40.0	>40.0
(°F) ^b	100.4 to 101.1	101.2 to 102.0	102.1 to 104.0	>104.0

The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

^a Participant should be at rest for all vital sign requirements.

^b Oral temperature; no recent hot or cold beverages or smoking.

Assessment of causality

- Did the Sponsor's product cause the AE?
- The determination of the likelihood that the Sponsor's product caused the AE will be provided by an investigator who is a qualified physician. The investigator's signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures that a medically qualified assessment of causality was done. This initialled document must be retained for the required regulatory time frame. The criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test product and the AE based upon the available information.
- **The following components are to be used to assess the relationship between the Sponsor's product and the AE;** the greater the correlation with the components and their respective elements (in number and/or intensity), the more likely the Sponsor's product caused the AE:
 - **Exposure:** Is there evidence that the participant was actually exposed to the Sponsor's product such as: reliable history, acceptable compliance assessment (diary, etc.), seroconversion or identification of vaccine virus in bodily specimen?
 - **Time Course:** Did the AE follow in a reasonable temporal sequence from administration of the Sponsor's product? Is the time of onset of the AE compatible with a vaccine-induced effect?
 - **Likely Cause:** Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or environmental factors?
 - **Rechallenge:** Was the participant re-exposed to the Sponsor's product in the study?
 - If yes, did the AE recur or worsen?
 - If yes, this is a positive rechallenge.
 - If no, this is a negative rechallenge.

(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the study is a single-dose vaccine study; or (3) Sponsor's product(s) is/are used only 1 time.)

NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND MAY HAVE BEEN CAUSED BY THE SPONSOR'S PRODUCT, OR IF RE-EXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR CLINICAL DIRECTOR, AND IF REQUIRED, THE IRB/IEC.

- **Consistency with study intervention profile:** Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or drug class pharmacology or toxicology?
- The assessment of relationship will be reported on the CRFs/worksheets by an investigator who is a qualified physician according to their best clinical judgment, including consideration of the above elements.
- Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product relationship).
 - Yes, there is a reasonable possibility of Sponsor's product relationship:
 - There is evidence of exposure to the Sponsor's product. The temporal sequence of the AE onset relative to the administration of the Sponsor's product is reasonable. The AE is more likely explained by the Sponsor's product than by another cause.
 - No, there is not a reasonable possibility of Sponsor's product relationship:
 - Participant did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor's product is not reasonable OR the AE is more likely explained by another cause than the Sponsor's product. (Also entered for a participant with overdose without an associated AE.)
- The investigator must review and provide an assessment of causality for each AE/SAE and document this in the medical notes.
- There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to the Sponsor. However, it is very important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the Sponsor.
- The investigator may change their opinion of causality in light of follow-up information and send an SAE follow-up report with the updated causality assessment.
- The causality assessment is 1 of the criteria used when determining regulatory reporting requirements.

Follow-up of AE and SAE

- The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by Sponsor to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.

- New or updated information will be recorded in the CRF.
- The investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of the information.

10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor

AE, SAE, and other reportable safety event reporting to Sponsor via electronic data collection tool

- The primary mechanism for reporting to the Sponsor will be the EDC tool.
 - Electronic reporting procedures can be found in the EDC data entry guidelines (or equivalent).
 - If the electronic system is unavailable for more than 24 hours, then the site will use the paper AE Reporting form.
 - Reference Section 8.4.1 for reporting time requirements.
- The site will enter the SAE data into the electronic system as soon as it becomes available.
- After the study is completed at a given site, the EDC tool will be taken off-line to prevent the entry of new data or changes to existing data.
- If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after the EDC tool has been taken off-line, then the site can report this information on a paper SAE form or by telephone (see next section).
- Contacts for SAE reporting can be found in the Investigator Study File Binder (or equivalent).

SAE reporting to the Sponsor via paper CRF

- If the EDC tool is not operational, facsimile transmission or secure e-mail of the SAE paper CRF is the preferred method to transmit this information to the Sponsor.
- In rare circumstances and in the absence of facsimile equipment, notification by telephone is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service.
- Initial notification via telephone does not replace the need for the investigator to complete and sign the SAE CRF pages within the designated reporting time frames.
- Contacts and instructions for SAE reporting and paper reporting procedures can be found in the Investigator Study File Binder (or equivalent).

10.4 Appendix 4: Medical Device and Drug-device Combination Products: Product Quality Complaints/Malfunctions: Definitions, Recording, and Follow-up

The recording and follow-up procedures described in the protocol apply to all medical devices/combination medicinal products as described below. For purposes of this section, medical devices/combination medicinal products in scope for device information collection include devices intended to be used by a study participant according to the study protocol, that are manufactured by the Sponsor or for the Sponsor by a third party, licensed by the Sponsor for human use and/or drug-device combination products as listed in Section 6.1.1. Product Quality Complaints/Malfunctions must be reported to the Sponsor.

10.4.1 Definitions

Medical Device - Devices, etc (other than regenerative medicine products) intended for use in the diagnosis, treatment or prevention of disease in humans or animals, or intended to affect the structure or functions of the body of humans or animals.

Combination Medicinal Product - A product comprised of two or more regulated components, ie, a drug and a device; a device and a cellular and tissue-based products; a cellular and tissue-based products and a drug; or a drug, a device, and a cellular and tissue-based products according to Japan regulations.

Malfunction - Failure of quality, safety and performance, etc of investigational device in a broad sense such as damage or operational failure.

Serious Adverse Event due to Malfunction - Any SAE due to malfunction in the characteristics and/or performance of a device (this study is a pre-filled syringe) as well as any inadequacy in the labeling or the instructions for use which might lead to or might have led to the death of a participant and/or the associated person or to a serious deterioration in their state of health.

Malfunction Which may Lead to Serious Adverse Events - Any malfunction of a medical device which might have led to the death of a participant and/or the associated person or to a serious deterioration in their state of health. "Which might have led to" means that there is the possibility that death or a serious deterioration might have occurred in a participant and/or the associated person, although these cases have not actually occurred.

10.4.2 Medical Device/Combination Medicinal Products – Documenting and Reporting

In order to fulfill Japan regulatory reporting obligations, medical device/combination medicinal product information will be collected. SAE due to malfunction will be reported to the Sponsor in the same time frame as SAEs as per Section 8.4.1 via CRF (paper or electronic) and as per data entry guidelines. All SAE due to malfunction will be followed until resolution, stabilization, until the event is otherwise explained, or the participant or associated person is lost to follow-up. Malfunction which may lead to serious adverse events will be reported to the Sponsor within 5 calendar days of learning of the information via a paper reporting form.

Sponsor shall review reported events by the investigator to fulfill the legal responsibility of notifying appropriate regulatory authorities and other entities as needed about certain safety information relating to medical devices/combination medicinal products being used in clinical studies.

10.4.3 Recording, Assessing Causality, and Follow-up of Adverse Events due to Malfunctions (serious and nonserious)

Recording

- When AEs due to malfunctions (serious or nonserious) occurs, it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory reports, and diagnostic reports) related to the event.
- Any AE due to malfunctions (serious or nonserious) occurring during the study will be recorded in the participant's medical records, in accordance with the investigator's normal clinical practice, and on the appropriate CRF (paper or electronic) as per instructions in the EDC data entry guidelines (or equivalent).
- It is important that the investigator provides an assessment of causality (relationship to the medical device) at the time of the initial report.

Assessing Causality

- A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship.
- The investigator will use clinical judgement to determine the relationship.
- Alternative causes should also be considered and investigated, such as underlying disease(s), concomitant therapy, and other risk factors as well as the temporal relationship of the event to study intervention administration.

Follow-up

- The investigator will perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by the Sponsor to elucidate the nature and/or causality of the event as complete as possible.

10.5 Appendix 5: Contraceptive Guidance

10.5.1 Definitions

Participants of Childbearing Potential (POCBP)

A participant assigned female sex at birth is considered fertile and capable of becoming pregnant following menarche and until becoming postmenopausal unless permanently sterile (see below):

If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.

Participants assigned female sex at birth who are in the following categories are not capable of becoming pregnant and, therefore, not considered POCPB:

- Premenarchal
- Premenopausal with 1 of the following:
 - Documented hysterectomy
 - Documented bilateral salpingectomy
 - Documented bilateral oophorectomy

For individuals with permanent infertility due to an alternate medical cause other than the above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.

Note: Documentation can come from the site personnel's review of the participant's medical records, medical examination, or medical history interview.

- Postmenopausal
 - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
 - A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in participants assigned female sex at birth who are not using hormonal contraception or HRT. However, in the absence of 12 months of amenorrhea, confirmation with two FSH measurements in the postmenopausal range is required.
 - Participants assigned female sex at birth who are on HRT and whose menopausal status is in doubt will be required to use one of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the study.

Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.

10.5.2 Contraception Requirements

Contraceptives allowed during the study include^a:
Highly Effective Contraceptive Methods That Have Low User Dependency^a <i>Failure rate of <1% per year when used consistently and correctly.</i>
<ul style="list-style-type: none"> • Progestogen- only contraceptive implant^{b,c} • IUS^{b,d} • Non-hormonal IUD • Bilateral tubal occlusion
<ul style="list-style-type: none"> • Azoospermic partner (vasectomized or secondary to medical cause, confirmed by medical history) All sexual partner(s) of the POCBP must be azoospermic. The participant must provide verbal confirmation of partner azoospermia during Medical History. If not, an additional highly effective method of contraception should be used. A spermatogenesis cycle is approximately 90 days.
Highly Effective Contraceptive Methods That Are User Dependent^a <i>Failure rate of <1% per year when used consistently and correctly.</i>
<ul style="list-style-type: none"> • Combined (estrogen- and progestogen- containing) hormonal contraception^{b,c} <ul style="list-style-type: none"> - Oral - Intravaginal - Transdermal - Injectable
<ul style="list-style-type: none"> • Progestogen-only hormonal contraception^{b,c} <ul style="list-style-type: none"> - Oral - Injectable
Sexual Abstinence
<ul style="list-style-type: none"> • All sexual partner(s) of the POCBP must be azoospermic. The participant must provide verbal confirmation of partner azoospermia during Medical History. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
Methods That Are Not Considered Highly Effective <i>Failure rate of >1% per year when used consistently and correctly.</i>
<ul style="list-style-type: none"> • Progesterone-only hormonal contraception where inhibition of ovulation is not the primary mode of action • Penile/external or vaginal/internal^e condom with or without spermicide • Cervical cap, diaphragm, or sponge with spermicide • A combination of penile/external condom with either cervical cap, diaphragm, or sponge with spermicide (double barrier methods).
<p>^a Typical use failure rates are higher than perfect-use failure rates (ie, when used consistently and correctly).</p> <p>^b Male condoms must be used in addition to female participant hormonal contraception.</p> <p>^c If locally required, in accordance with CTFG guidelines, acceptable hormonal contraceptives are limited to those which inhibit ovulation.</p> <p>^d IUS is a progestin releasing IUD.</p> <p>^e Vaginal/internal condom used for contraceptive purposes</p> <p>Note: The following are not acceptable methods of contraception:</p> <ul style="list-style-type: none"> - Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM - Penile/external and vaginal/internal^f condom should not be used together (due to risk of failure with friction). <p>^f Vaginal/internal condom used for contraceptive purposes.</p>

10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical Research

1. Definitions

- a. Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.¹
- b. Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as related to drug/vaccine response.²
- c. Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of variations in DNA sequence on drug/vaccine response.²
- d. DNA: Deoxyribonucleic acid.
- e. RNA: Ribonucleic acid.

2. Scope of Future Biomedical Research^{3, 4}

The specimens consented and/or collected in this study as outlined in Section 8.9 will be used in various experiments to understand:

- ☐ The biology of how drugs/vaccines work
- ☐ Biomarkers responsible for how a drug/vaccine enters and is removed by the body
- ☐ Other pathways with which drugs/vaccines may interact
- ☐ The biology of disease

The specimen(s) may be used for future assay development and/or drug/vaccine development.

It is now well recognized that information obtained from studying and testing clinical specimens offers unique opportunities to enhance our understanding of how individuals respond to drugs/vaccines, enhance our understanding of human disease and ultimately improve public health through development of novel treatments targeted to populations with the greatest need. All specimens will be used by the Sponsor or those working for or with the Sponsor.

3. Summary of Procedures for Future Biomedical Research^{3, 4}

a. Participants for Enrollment

All participants enrolled in the clinical study will be considered for enrollment in future biomedical research.

b. Informed Consent

Informed consent for specimens (ie, DNA, RNA, protein, etc) will be obtained during screening for protocol enrollment from all participants or legal guardians, at a study visit by the investigator or his or her designate. Informed consent for future biomedical research should be presented to the participants on the visit designated in the SoA. If delayed, present consent at next possible Participant Visit. Consent forms signed by the participant will be kept at the clinical study site under secure storage for regulatory reasons.

A template of each study site's approved informed consent will be stored in the Sponsor's clinical document repository.

c. eCRF Documentation for Future Biomedical Research Specimens

Documentation of participant consent for future biomedical research will be captured in the eCRFs. Any specimens for which such an informed consent cannot be verified will be destroyed.

d. Future Biomedical Research Specimen(s)

Collection of specimens for future biomedical research will be performed as outlined in the SoA. In general, if additional blood specimens are being collected for future biomedical research, these will usually be obtained at a time when the participant is having blood drawn for other study purposes.

4. Confidential Participant Information for Future Biomedical Research^{3, 4}

In order to optimize the research that can be conducted with future biomedical research specimens, it is critical to link participants' clinical information with future test results. In fact, little or no research can be conducted without connecting the clinical study data to the specimen. The clinical data allow specific analyses to be conducted. Knowing participant characteristics like sex, age, medical history and intervention outcomes are critical to understanding clinical context of analytical results.

To maintain privacy of information collected from specimens obtained for future biomedical research, the Sponsor has developed secure policies and procedures. All specimens will be single-coded per ICH E15 guidelines as described below.

At the clinical study site, unique codes will be placed on the future biomedical research specimens. This code is a random number which does not contain any personally identifying information embedded within it. The link (or key) between participant identifiers and this unique code will be held at the study site. No personal identifiers will appear on the specimen tube.

5. Biorepository Specimen Usage^{3, 4}

Specimens obtained for the Sponsor will be used for analyses using good scientific practices. Analyses using the future biomedical research specimens may be performed by the Sponsor, or an additional third party (eg, a university investigator) designated by the Sponsor. The investigator conducting the analysis will follow the Sponsor's privacy and confidentiality requirements. Any contracted third party analyses will conform to the specific scope of analysis outlined in future biomedical research protocol and consent. Future biomedical research specimens remaining with the third party after specific analysis is performed will be reported to the Sponsor.

6. Withdrawal From Future Biomedical Research^{3, 4}

Participants may withdraw their consent for FBR and ask that their biospecimens not be used for FBR. Participants may withdraw consent at any time by contacting the study investigator. If medical records for the study are still available, the investigator will contact the Sponsor using the designated mailbox (clinical.specimen.management@MSD.com). Subsequently, the participant's specimens will be flagged in the biorepository and restricted to study use only. If specimens were collected from study participants specifically for FBR, these specimens will be removed from the biorepository and destroyed. Documentation will be sent to the investigator confirming withdrawal and/or destruction, if applicable. It is the responsibility of the investigator to inform the participant of completion of the withdrawal and/or destruction, if applicable. Any analyses in progress at the time of request for withdrawal/destruction or already performed before the request being received by the Sponsor will continue to be used as part of the overall research study data and results. No new analyses would be generated after the request is received.

If the medical records for the study are no longer available (eg, if the investigator is no longer required by regulatory authorities to retain the study records) or the specimens have been completely anonymized, there will no longer be a link between the participant's personal information and their specimens. In this situation, the request for withdrawal of consent and/or destruction cannot be processed.

7. Retention of Specimens^{3, 4}

Future biomedical research specimens will be stored in the biorepository for potential analysis for up to 20 years from the end of the study. Specimens may be stored for longer if a regulatory or governmental authority has active questions that are being answered. In this special circumstance, specimens will be stored until these questions have been adequately addressed.

Specimens from the study site will be shipped to a central laboratory and then shipped to the Sponsor-designated biorepository. If a central laboratory is not utilized in a particular study, the study site will ship directly to the Sponsor-designated biorepository. The specimens will be stored under strict supervision in a limited access facility which operates to assure the integrity of the specimens. Specimens will be destroyed according

to Sponsor policies and procedures and this destruction will be documented in the biorepository database.

8. Data Security^{3, 4}

Databases containing specimen information and test results are accessible only to the authorized Sponsor representatives and the designated study administrator research personnel and/or collaborators. Database user authentication is highly secure, and is accomplished using network security policies and practices based on international standards to protect against unauthorized access.

9. Reporting of Future Biomedical Research Data to Participants^{3, 4}

No information obtained from exploratory laboratory studies will be reported to the participant, family, or physicians. Principle reasons not to inform or return results to the participant include: lack of relevance to participant health, limitations of predictive capability, and concerns regarding misinterpretation.

If important research findings are discovered, the Sponsor may publish results, present results in national meetings, and make results accessible on a public website in order to rapidly report this information to doctors and participants. Participants will not be identified by name in any published reports about this study or in any other scientific publication or presentation.

10. Future Biomedical Research Study Population^{3, 4}

Every effort will be made to recruit all participants diagnosed and treated on Sponsor clinical studies for future biomedical research.

11. Risks Versus Benefits of Future Biomedical Research^{3, 4}

For future biomedical research, risks to the participant have been minimized and are described in the future biomedical research informed consent.

The Sponsor has developed strict security, policies, and procedures to address participant data privacy concerns. Data privacy risks are largely limited to rare situations involving possible breach of confidentiality. In this highly unlikely situation, there is risk that the information, like all medical information, may be misused.

12. Questions

Any questions related to the future biomedical research should be emailed directly to clinical.specimen.management@MSD.com.

13. References

1. National Cancer Institute [Internet]: Available from <https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45618>
2. International Council on Harmonisation [Internet]: E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories. Available from <http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/definitions-for-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-and-sample-cod.html>
3. Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs and Investigational Site Staff. Available at <http://i-pwg.org/>
4. Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at <http://i-pwg.org/>

10.7 Appendix 7: Country-specific Requirements

Not applicable.

10.8 Appendix 8: Abbreviations

Abbreviation	Expanded Term
AE	adverse event
APaT	All-Participants-as-Treated
CFR	Code of Federal Regulations
CI	confidence interval
cLDA	constrained Longitudinal Data Analysis
CONSORT	Consolidated Standards of Reporting Trials
CRF	case report form
CSR	clinical study report
CTFG	Clinical Trial Facilitation Group
deOAc	de-O-acetylated
DNA	deoxyribonucleic acid
ECG	electrocardiogram
ECI	event of clinical interest
ECL	electrochemiluminescence
eCRF	electronic Case Report Form
EDC	electronic data collection
EMA	European Medicines Agency
EU	European Union
eVRC	Electronic Vaccination Report Card
FAS	Full Analysis Set
FBR	Future Biomedical Research
FDA	Food and Drug Administration
FDAAA	Food and Drug Administration Amendments Act
FSH	follicle-stimulating hormone
GCP	Good Clinical Practice
GMC	geometric mean concentration
GMFR	geometric mean fold rise
GMT	geometric mean titer
hCG	human chorionic gonadotropin
HIV	human immunodeficiency virus
HRT	hormone-replacement therapy
IB	Investigator's Brochure
ICF	Informed Consent Form
ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
ICMJE	International Committee of Medical Journal Editors
IEC	Independent Ethics Committee
IgG	Immunoglobulin G
IM	intramuscular(ly)
IND	Investigational New Drug
IPD	invasive pneumococcal disease
IRB	Institutional Review Board

Abbreviation	Expanded Term
IRT	interactive response technology
IUD	intrauterine device
IUS	intrauterine hormone-releasing system
LAM	lactational amenorrhea method
M&N	Miettinen and Nurminen
MOPA	Multiplexed Opsonophagocytic Assay
mRNA	messenger RNA
NIP	National Immunization Program
OPA	opsonophagocytic activity
PCV	pneumococcal conjugate vaccine
PCV13	pneumococcal 13-valent conjugate vaccine (Prevnam 13™)
Pn ECL	pneumococcal electrochemiluminescence
PnPs	pneumococcal polysaccharide
POCBP	Participant/participants of childbearing potential
PP	per-protocol
PPSV23	pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX™23) (Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F)
REML	restricted maximum likelihood
RNA	ribonucleic acid
SAE	serious adverse event
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
SLAB	Supplemental laboratory test(s)
SoA	Schedule of Activities
sSAP	supplemental Statistical Analysis Plan
SUSAR	suspected unexpected serious adverse reaction
US	United States
VRC	Vaccination Report Card

11 REFERENCES

- | | | |
|---|--|----------|
| [Anttila, M., et al 1999] | Anttila M, Voutilainen M, Jäntti V, Eskola J, Käyhty H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against <i>Streptococcus pneumoniae</i> . Clin Exp Immunol 1999;118(3):402-7. | [03QY70] |
| [Burton, Robert L. and Nahm, Moon H. 2006] | Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006;13(9):1004-9. | [03QT2R] |
| [Centers for Disease Control and Prevention 2010] | Centers for Disease Control and Prevention. Prevention of Pneumococcal Disease Among Infants and Children - Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine; Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(RR-11):1-19. | [03RSB6] |
| [Centers for Disease Control and Prevention 2015] | Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Hamborsky J, Kroger A, Wolfe S, editors. Washington (DC): Department of Health and Human Services (HHS); c2015. Chapter 6, Vaccine administration; p. 79-106. | [0508PV] |
| [Centre for Disease Control and Prevention 2018] | Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report: emerging infections program network: <i>Streptococcus pneumoniae</i> , 2018. Washington (DC): Department of Health and Human Services (HHS); 2018. | [05J8JP] |
| [CLOPPER, C. J. and PEARSON, E. S. 1934] | Clopper CJ, Pearson ES. The use of confidence of fiducial limits illustrated in the case of the binomial. Biometrika 1934;26(4):404-13. | [03RRVC] |
| [Drijkoningen, J. J 2014] | Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014 May;20 Suppl 5:45-51. | [04NFHN] |

[Epidemiological Information of Invasive Pneumococcal Infection in Children and Adults 2020]	Epidemiological Information of Invasive Pneumococcal Infection in Children and Adults [Internet]. [place unknown]: Epidemiological Information of Invasive Pneumococcal Infection in Children and Adults; c2019. [The Study on Establishment of Surveillance for Invasive Bacterial Infections in Adults in 2020]; [cited 2022 Jul 18]; [about 3 screens]. Available from: https://ipd-information.com/?page_id=58 . Japanese.	[083L3F]
[Farrington, C. P. 1990]	Farrington CP, Manning G. Test Statistics and Sample Size Formulae for Comparative Binomial Trials with Null Hypothesis of Non-Zero Risk Difference or Non-Unity Relative Risk. Stat Med Vol. 9,1447-1454 (1990)	[04FS6L]
[Food and Drug Administration 2007]	Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Rockville, MD. Sep 2007.	[05B4S4]
[Golden, A. R., et al 2016]	Golden AR, Adam HJ, Zhanel GG. Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. Vaccine. 2016 May 17;34(23):2527-30.	[04KWF0]
[Janssens, J. P. 2004]	Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis. 2004 Feb;4:112-24.	[04VTNJ]
[Liang, K-Y and Zeger, S. L. 2000]	Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya: The Indian Journal of Statistics 2000;62(Series B, Part 1):134-48.	[00V5V6]
[Marcy, S. M., et al 2004]	Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Connell Jones M, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004;22:551-6.	[03PVW0]
[Miettinen, O. and Nurminen, M. 1985]	Miettinen O, Nurminen M. Comparative Analysis of Two Rates. Stat Med 1985;4:213-26.	[03QCDT]

[Miller, Elizabeth, et al 2011]	Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. <i>Lancet Infect Dis</i> 2011;11(10):760-8.	[03RKY7]
[Moore, M. R., et al 2015]	Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. <i>Lancet Infect Dis</i> . 2015 Feb 3. [Epub ahead of print].	[043MRP]
[National Institute of Infectious Diseases 2018]	National Institute of Infectious Diseases. [Current situation of invasive pneumococcal disease among children following the introduction of 13-valent pneumococcal conjugate vaccine]. <i>Infectious Agents Surveillance Report</i> . 2018 Jul;39(7):107-28. Japanese.	[06FHG4]
[Pilishvili, T. 2015]	Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. <i>Am J Prev Med</i> . 2015 Dec;49(6 suppl 4):S383-90.	[04WP9S]
[Romero-Steiner, S., et al 1997]	Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against streptococcus pneumoniae using differentiated HL-60 cells. <i>Clin Diagn Lab Immunol</i> 1997;4(4):415-22.	[03NWQ5]
[Sando, E., et al 2019]	Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, et al. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: the Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE). <i>Vaccine</i> . 2019;37:2687-93. Erratum in: <i>Vaccine</i> . 2020;38:3404.	[05JDDF]

[Shimbashi, R., et al 2020]	Shimbashi R, Suzuki M, Chang B, Watanabe H, Tanabe Y, Kuronuma K, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan, 2013-2017. Emerg Infect Dis. 2020 Oct;26(10):2378-86.	[06CW59]
[Sunagawa, T., et al 2018]	Sunagawa T, Kozuki A, Fukuzumi M, et al. Epidemiological surveillance of invasive pneumococcal disease in Japan, 2013 to 2017: research for adult IPD surveillance: MHLW science research grants: summary report. 2018. 4 p. Japanese.	[05348N]
[Troeger, C., et al 2018]	Troeger C, Blacker BF, Khalil IA, Rao PC, Cao S, Zimsen SRM, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018 Nov;18:1191-210.	[07XTBZ]
[U.S. Food and Drug Administration 2009]	U.S. Food and Drug Administration (CDER, CBER, CDRH). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims [Internet]. Washington: U.S. Department of Health and Human Services; 2009. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf	[04MG9J]
[Ubukata, K., et al 2018]	Ubukata K, Takata M, Morozumi M, Chiba N, Wajima T, Hanada S, et al. Effects of pneumococcal conjugate vaccine on genotypic penicillin resistance and serotype changes, Japan, 2010-2017. Emerg Infect Dis. 2018 Nov;24(11):2010-20.	[05JDDG]
[van der Linden, M., et al 2015]	van der Linden M, Falkenhorst G, Perniciaro S, Imohl M. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One. 2015 Jul 1;10(7):e0131494.	[04KVRV]